

Segreteria Sin

Da: c.gasperini <c.gasperini@omceoromapec.it>
Inviato: domenica 16 aprile 2023 13:00
A: info@neuro.it
Oggetto: Candidatura Gasperini GDS Sclerosi Multipla della SIN
Allegati: CV claudio gasperini english aprile 2023 .pdf; Programma Gasperini.pdf

Gentilissimi,
con la presente si invia documentazione di supporto per la mia candidatura a
Coordinatore del Gruppo di Studio Sclerosi Multipla della SIN per il biennio 2023-2025

In allegato:

1. CV
2. programma di attività

Cordialmente
Claudio Gasperini

CURRICULUM VITAE AND SCIENTIFIC ACTIVITIES CLAUDIO GASPERINI

PERSONAL DATA

Birth date: 02/02/1962

Place of birth: Riano (Rome), Italy

Address: Via Giuseppe Ferrari, 4 - 00195 Rome

EDUCATION

1982 - School-leaving certificate achieved in "G. Piazzini" secondary school of Morlupo (Rome).

1989 - Degree in Medicine and Surgery achieved in University "La Sapienza" of Rome, with the results of 110/110 *cum laude* presenting the results of an original research with the following title "Fattori Prognostici dell'Ictus in Fase Acuta", supervisor Prof. Cesare Fieschi.

1989 - Qualification to practice of medical profession.

1992 - Winner of a fellowship of the "Cenci Bolognetti" Foundation due to a project on the role of Heat shock proteins in Multiple Sclerosis.

1993 - Specialization Certificate in Neurology achieved in the Neuroscience Department of the University "La Sapienza" - Rome, with the results of 70/70 *cum laude* and thesis about "Studio controllato su potenziali fattori di rischio nella comparsa di esacerbazioni in pazienti affetti da Sclerosi Multipla".

1993. Winner of a fellowship of the "Multiple Sclerosis Italian Association (AISM)" due to a project on the employment of new MRI quantitative techniques RMN in MS.

1991-2002 - Teaching of Rehabilitative Neurology in the Therapy of Rehabilitation School of Carlo Forlanini Hospital in Rome.

From 1996 to 98 - Consulting Neurologist in Multiple Sclerosis Center of S. Camillo Hospital in Rome, Lancisi Division.

1998 - Title of "Research Doctor" in Neuroscience Department of University "La Sapienza" - Rome.

From 3.2.2104 National Academic qualification as Associate Professor in Neurology (MED 26) by National competition. (<https://loginmiur.cineca.it>)

From 1 28.3.2017 National Academic qualification as Full Professor in Neurology (MED 26) by

National competition (<https://loginmiur.cineca.it>)

WORK AND SCIENTIFIC EXPERIENCE

Registration Number in the register of Medical Doctors: 41017

From 1993 Member of the Italian neurological Society (SIN)

1999 - Coordinator of the following research project sponsored by “Multiple Sclerosis Italian Association (AISM) ”: Effetto del trattamento con Interferon Beta sull’evoluzione dell’atrofia cerebrale in pazienti con SMRR.

2000 - Member of the Coordinator Scientific Committee of an Italian Multicentric Trial on the efficacy of a treatment association of Interferon Beta plus Methylprednisolone vs Interferon Beta alone in patients affected by Secondary Progressive Multiple Sclerosis-

2001 - Coordinator in the following research project sponsored by “Multiple Sclerosis Italian Association (AISM)”: Correlazione tra RMN e markers immunologici.

2000 - 2022: Principal investigator of several Phase II e III clinical trials evaluating the effect of new treatments in Multiple Sclerosis according GCP

From 1999 to 2019 - 1st Level Medical Manager in Neuroscience Department of Azienda Ospedaliera S. Camillo Forlanini Rome. Neurological Department of Azienda Ospedaliera San Camillo Forlanini – Circonvallazione Gianicolense 87 00152 Roma Italy

From 2006 Teacher of Neurology in S. Andrea Hospital University La Sapienza of Rome

2009-2015 Member of the Steering Committee in the Italian Society of Neurology, Neuroradiology and Neurosurgery (SNO)

2009-2018: Referee of several journals peer review: Neurology, Annals of Neurology, Multiple Sclerosis, J of Neurology-Psychiatry-Neurosurgery, European Journal of Neurology, Expert opinion in Neurology, J of Neurology.

2013-2018: Member of the Editorial Board of BMC Neurology

From 2018 : Regional delegate of the Association Neurology Emergency (ANEU)

From 2019 Head of Neurology Unit Department of San Camillo Forlanini Hospital – Circonvallazione Gianicolense 87 00152 Roma Italy

From 2021 Coordinator of the Italian Neurological Society (SIN) for the Study Group on Multiple Sclerosis

From 2022 Full membership of the European Academy of Neurology (EAN).

From 2022 Italian delegate of theECTRIMS Council

FOREIGN RESIDENCES AND INTERNATIONAL COMMISSIONS

1993 - Study residence of one year in "*The NMR research group of Multiple Sclerosis* - Institute of Neurology - National Hospital of London, directed by Prof. Ian McDonald.

1996-1997 - Member of a research group of the European Community with regards to multicentric trials on the optimisation of the MRI usage in Multiple Sclerosis (MAGNIMS).

1998 - Member of a Europe-United States Task Force on the MRI usage in Multiple Sclerosis.

From 2012. Member of the Steering Committee of MAGNIMS group.

SCIENTIFIC ACTIVITIES

Dr. Claudio Gasperini scientific activities are documented by more than 280 publications, in peer review journals.

Particular field of interest is represented by Multiple Sclerosis.

In this field, more importance was given to the epidemiological evaluation, diagnosis and therapy of the disease. Moreover, the pathogenic aspect of the natural history of disease was analysed utilizing MRI quantitative and qualitative techniques.

From 2019 Head of Neurology in the Department of Neurosciences Azienda Ospedaliera S Camillo Forlanini

From 2022 Full membership of the European Academy of Neurology (EAN).

From 2022 Italian delegate of theECTRIMS Council

He has been principal investigator in several clinical trials in PHASE II and III according GCP

SCIENTIFIC COLLABORATIONS IN ITALY AND OTHER STATES

- The NMR research group of Multiple Sclerosis - Institute of Neurology - National Hospital of London Prof. Ian McDonald, Prof DH Miller, Prof AJ Thompson, Prof. O. Ciccarelli

- The Neurologische Universitatas-Poliklinik und Abteilung Neuroradiologie, Kantonsspital, Basel, Switzerland, Prof Kappos.

- The Afdeling Radiodiagnostiek, Vrje Universiteit, Amsterdam, The Netherlands, Prof . Barkhof.

- S. Raffaele Neurology Department – Milan: Prof Filippi.
- University of Siena Neurology Department: Prof Nicola De Stefano
- University of Oxford: Prof. J Palace
- University of Graz: Prof C. Enzinger
- University of Barcellona: Prof. X Montalban and Prof. A Rovira
- University of Verona: Prof. M Calabrese
- Univeristy of Naples: Prof. G. Tedeschi
- University of Bari: Prof. M Trojano
- University of Firenze: Prof. M. Amato

SELECTED PAPERS

(H-Index Scopus: 52).

1991

1. Irreversible total blindness in Multiple Sclerosis

Gasperini C, Pozzilli C, Bernardi S.

Italian Journal of Neurological Sciences.

1991;12:329

(I.F 2.28)

1993

2. Anatomical and Functional correlates of cognitive deficit in Multiple Sclerosis.

Pozzilli C, **Gasperini C**, Anzini A, Grasso MG, Ristori G, Fieschi C.

J. Neurol. Sci. 115 .S55-S58, 1993.

(I.F 5.98)

1994

3. A controlled trial of Mitoxantrone in Multiple Sclerosis: Serial MRI evaluation at one year.

Bastianello S, Pozzilli C, D'Andrea F, Millefiorini E, Trojano M, Morino S, **Gasperini C**, Bozzao A, Gallucci M, Andreula C, Bozzao L, Gambi D, Prencipe M.

Can. J. Neurol. Sci. 1994; 21:266-270.

(I.F.1.1)

4. Diagnostic problems in "clinically definite" multiple sclerosis patients with normal CSF and multiple MRI abnormalities Fieschi C, **Gasperini C, Ristori G, Bastianello S, Girmenia F, Leuzzi V, Buttinelli C, Pozzilli C, Rasura M.**

European Journal of Neurology 1994; 1:127-133.

(I.F. 3.9)

1995

5. Non-invasive assessment of Mitoxantrone cardiotoxicity in relapsing remitting Multiple Sclerosis.

De Castro S, Cartoni D, Millefiorini E, Funaro S, **Gasperini C**, Morino S, Tallarico D, Beni S.

J. of Clinical Pharmacology 1995; 35: 627-632.

(I.F. 2)

6. Patients with clinically definite multiple sclerosis, white matter abnormalities on MRI, and normal CSF: if not multiple sclerosis, what is it?

Fieschi C, **Gasperini C**, Ristori G, Bastianello S, Girmenia F, Leuzzi V, Buttinelli C, Rasura M.

Journal of Neurol, Neurosurg. and Psychiatry. 1995; 58 (2): 255-256.

(I.F. 7.4)

7. A controlled study of potential risk factors preceding exacerbation in Multiple Sclerosis. **Gasperini C**, Grasso MG, Fiorelli M, Millefiorini E, Morino S, Anzini A, Colleluori A, Salvetti M, Buttinelli C, Pozzilli C.

Journal of Neurol, Neurosurg. and Psychiatry. 1995; 59:303-305.

(I.F. 7.4)

8. Human recombinant interferon beta (rebif) in the treatment of relapsing-remitting multiple sclerosis.

Pozzilli C, Bastianello S, Koudriavtseva T, **Gasperini C**, Bozzao A, Galgani S, Paolillo A, Millefiorini E, Buttinelli C, Pierciaccante G, Piazza G, Bozzao L, Fieschi C.

Multiple Sclerosis 1995 1, S28-S31.

(I.F. 4.84)

1996

9. High dose contrast-enhanced MRI in multiple sclerosis.

Koudriavtseva T, Pozzilli C, De Biasi C, Iannilli M, Trasimeni G, **Gasperini C**, Argentino C, Gualdi GF.

Neuroradiology 1996, 38:S5-S9.

(I.F. 2.3)

10. MRI in the differential diagnosis of multiple sclerosis without CSF abnormalities

Gasperini C, Bastianello S, Ristori G, Paolillo A, Giugni E, Colonnese C, Fieschi C, Bozzao L..

International Journal of Neuroradiology; 1996; 2:117-122.

(I.F. 2.3)

11. MRI Texture in normal appearing white matter of MS patients: relationship to other quantitative MRI and clinical parameters.

Gasperini C, Horsfield MA, Thorpe J, Kidd D, Barkers GJ, Tofts PS, MacManus DG, Thompson AJ, Miller DH, McDonald WI.

JMRI 1996; 6:580-584.

(I.F. 3.6)

12. Magnetic resonance imaging and clinical activity before and after treatment with human recombinant beta interferon: a short term study in relapsing remitting multiple sclerosis.

Pozzilli C, Bastianello S, Koudriavtseva T, **Gasperini C**, Bozzao A, Millefiorini E, Galgani S, Buttinelli C, Pierciaccante G, Piazza G, Bozzao L, Fieschi C.

Journal of Neurol, Neurosurg and Psychiatry. 1996; 61:251-258.

(I.F. 7.4)

1997

13. The influence of clinical relapse and steroid therapy on development of Gd-enhancing lesions: a longitudinal MRI study in relapsing remitting multiple sclerosis.

Gasperini C, Pozzilli C, Bastianello S, Koudriavtseva T, Thompson AJ, Horsfield MA, Colletuori A, Millefiorini E, Piazza G, Bozzao L, Fieschi C. Acta Neurol Scand 1997; 95:201-207.

(I.F. 3.1)

14. Gd-enhanced baseline MRI predicts clinical and MRI disease activity in relapsing remitting multiple sclerosis.

Koudriavtseva T, Thompson AJ, Fiorelli M, **Gasperini C**, Bastianello S, Paolillo A, Pisani A, Bozzao A, Galgani S, Pozzilli C. Journal of Neurol, Neurosurg and Psychiatry. 1997; 62:285-287.

(I.F. 7.4)

15. Randomized double-blind placebo controlled trial of Mitoxantrone in relapsing remitting multiple sclerosis: 24 month clinical and MRI results.

E Millefiorini, **C Gasperini**, C Pozzilli, F D'Andrea, S Bastianello, M Trojano, S Morino, V Bresia Morra, A Bozzao, A Calo', ML Bernini, D Gambi, M Prencipe.. J of Neurology 1997; 244: 153-159.

(I.F. 3.8)

16. Fast Spin-echo and Fast Flair sequences versus conventional spin echo for quantification of multiple sclerosis

S Bastianello, A Bozzao, A Paolillo, E Giugni, **C Gasperini**, T Koudriavtseva, E Millefiorini, MA Horsfield, C Colonnese, D Toni, M Fiorelli, C Pozzilli, L Bozzao.

AJMR 1997; 18: 699-704.

(I.F. 3.6)

17. Quantitative magnetic resonance analysis in vascular dementia.

F Giubilei, S Bastianello, A Paolillo, **C Gasperini**, et al.

J of Neurology 1997; 244: 246-251.

(I.F. 3.8)

18. MRI measure and their relations with clinical disability in relapsing remitting and secondary progressive multiple sclerosis.

E Giugni, C Pozzilli, S Bastianello, **C Gasperini**, A Paolillo, T Koudriavtseva, M Frontoni, D Farina, L Bozzao.

Multiple Sclerosis 1997; 3: 221-225.

(I.F. 4.8)

19. Interscanner variation in brain MRI lesion load measurements in MS: Implications for clinical trials.

M Filippi, JH Waesberghe, MA Horsfield, S Bressi, **C Gasperini**, TA Yoursry, ML Gawne-Cain, SP Morrissey, MA Rocca, F Barkhof, GJ Lycklama A Nijeholt, S Bastianello, DH Miller.

Neurology 1997; 49: 371-377.

(I.F. 7.6)

20. Differential diagnosis in Multiple Sclerosis

C. Gasperini.

Int. MS Journal. 1997 Vol. 4 No 1.

(I.F. 0.69)

21. No increase of serum autoantibodies during therapy with recombinant human interferon Beta 1a in relapsing remitting multiple sclerosis.

C Colosimo, C Pozzilli, M Frontoni, D Farina, T Koudriavtseva, **C Gasperini**, M Salvetti, G Valesini.

Acta Neurol Scand. 1997. 96: 372-374.

(I.F. 3.1)

22. Four-year follow-up of a case of acute multiple sclerosis of the Marburg type.

Giubilei F, Sarrantonio A, Tisei P, **Gasperini C**, Salvetti M.

Ital. J. Neurol. Sci. 1997: 18: 163-166.

(I.F. 2.28)

1998

23. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis

C Gasperini, C Pozzilli, S Bastianello, T Koudriavtseva, S Galgani, E Millefiorini, A Paolillo, MA Horsfield, L Bozzao, C Fieschi.

Neurology 1998; 50 (2): 403-405.

(I.F. 7.6)

24. Development of Neutralizing Antibodies in patients with Relapsing Remitting Multiple Sclerosis treated with Interferon Beta 1a. G Antonelli, F Bagnato, C Pozzilli, E Simeoni, S Bastianello, M Currenti, C Fieschi, **C Gasperini**, M Salvetti, F Dianzani.

J Interferon Research 1998.

(I.F. 2.4)

25. Serum Amyloid A protein is elevated in Relapsing Remitting Multiple Sclerosis.

G Ristori, F Laurenti, P Stacchini, **C Gasperini**, C Buttinelli, C Pozzilli, M Salvetti. J Neuroimmunology 1998

(I.F. 2.6)

26. Determinants of Gd-enhanced MRI response to IFNB 1a treatment in relapsing remitting multiple sclerosis.

T Koudriavtseva, C Pozzilli, M Fiorelli, C Gasperini, F Bagnato, S Galgani, M Frontoni, O Ciccarelli, S Bastianello.

Multiple Sclerosis 1998.

(I.F. 4.84)

27 The effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis.

M Filippi, ML Gawne-Cain, **C Gasperini**, JH van Waesberghe, J Grimaud, H Ader, F Barkhof, MP Sormani, DH Miller.

Neurology 1998 50: 230-237.

(I.F. 7.6)

28. Correlation between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis: a multicentre longitudinal study.

PD Molineaux, M Filippi, F Barkhof, **C Gasperini**, T Yousry, L Truyen HM Lai, MA Rocca, OF Moseley, DH Miller.

Ann Neurol 1998 43 (3): 332-339

(I.F. 9.9)

29. A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis.

M Filippi, G Mastronardo, S Bastianello, MA Rocca, M Rovaris, **C Gasperini**, C Pozzilli, G Comi. J Neurol Sciences 1998.

(I.F. 5.98)

30. A multicentre longitudinal study comparing the sensitivity of monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: implications for phase II clinical trials.

M Filippi, M Rovaris, R Capra, **C Gasperini**, TA Yousry, MP Sormani, F Prandini, V Martinelli, S Bastianello, I Kuhne, C Pozzilli, G Comi.

Brain 1998 Oct;121 (Pt 10):2011-20.

(I.F. 10.84)

31. A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis.

M Filippi, M Rovaris, **C Gasperini**, R Capra, S Bastianello, I Kuhne, TA Yousry.

Journal of Neuroimaging 1998; 8 (2): 88: 93

(I.F. 1.9)

32. A longitudinal study evaluating the sensitivity of enhanced MR in multiple sclerosis: effect of gadolinium dose and magnetization transfer contrast.

S Bastianello, **C Gasperini**, A Paolillo, E Giugni, O Ciccarelli, MP Sormani, M Rovaris, C Pozzilli, M Filippi. AJMR 1998

(I.F. 3.6)

33. Frequency and significance of antinuclear antibodies in multiple sclerosis.

C Pozzilli, S Bastianello, **C Gasperini**, M Salvetti. Neurology 1998.

(I.F. 7.6)

34. Detecting new lesion formation in multiple sclerosis: the relative contributions of monthly dual-echo and T1 weighted scans after triple dose gadolinium.

M Filippi, G Mastronardo, MA Rocca, R Capra, **C Gasperini**, M Rovaris, S Bastianello, G Comi.

European Neurology 1998.

(I.F. 3.9)

35. MRI evolution of new MS lesions enhancing after different doses of gadolinium.

M Rovaris, G Matronardo, **C Gasperini**, F Prandini, TA Yousry, M Filippi. Acta Neurol Scand 1998

(I.F. 3.1)

1999

36. Magnetic resonance imaging outcome of new enhancing lesions in multiple sclerosis patients treated with rIFNβ 1a.

A Paolillo, S Bastianello, M Frontoni, **C Gasperini**, E Giugni, O Ciccarelli, F Bagnato, T Koudriatseva, C Pozzilli. J of Neurology 1999; 246 (6):443-8.

(I.F. 3.8)

37. A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions.
M Filippi, M Rovaris, S Bastianello, **C Gasperini**, D Origgi, P Reganati, C Pozzilli, G Comi.
J of Neurology 1999; 246 (2): 97-106
(I.F. 3.8)
38. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials.
Sormani MP, Bruzzi P, Miller DH, **Gasperini C**, Barkhof F, Filippi M.
J Neurol Sci 1999; 163 (1):74-80.
(I.F. 5.98)
39. Predictive value of gadolinium enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta analysis. Gadolinium MRI Meta-analysis Group.
Kappos L, Moeri D, Radue EW, Schoetzau A, Schwikert K, Barkhof F, Miller DH, Guttman CR, Weiner HL, **Gasperini C**, Filippi M.
Lancet 1999; 353 (9157): 964-9.
(I.F. 53.2)
40. Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results.
Sormani MP, Molineux PD, **Gasperini C**, Barkhof F, Yousry TA, Miller DH, Filippi M.
J Neurol Neurosurg Psychiatry 1999; 66 (4): 465-9
(I.F. 7.4)
41. IL-12 mediated NKR1A up-regulation and consequent enhancement of endothelial transmigration of V delta 2+ TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients.
Poggi A, Zocchi MR, Costa P, Ferrero E, Borsellino G, Placido R, Galgani S, Salvetti M, **Gasperini C**, Ristori G, Brosnan CF, Battistini L.
J Immunol 1999; 162 (7): 4349-54.
(I.F. 5.2)
42. Fatigue and magnetic resonance imaging activity in multiple sclerosis
Mainero C, Faroni J, **Gasperini C**, Filippi M, Giugni E, Ciccarelli O, Rovaris M, Bastianello S, Comi G, Pozzilli C.
J Neurol 1999; 246 (6): 454-8.
(I.F. 3.8)
43. Magnetic resonance outcome of new enhancing lesions in patients with relapsing remitting multiple sclerosis.
Ciccarelli O, Giugni E, Paolillo A, Mainero C, **Gasperini C**, Bastianello S, Pozzilli C.
Eur J Neurol 1999; 6 (4): 455-9.
(I.F. 3.9)
44. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology.
Filippi M, Rovaris M, Capra R, **Gasperini C**, Prandini F, Martinelli V, Horfield MA, Bastianello S, Sormani MP, Pozzilli C, Comi G.
J Neurol Neurosurg Psychiatry 1999; 67 (3): 386-9

(I.F. 7.4)

45. Disease activity in multiple sclerosis studied by weekly triple dose magnetic resonance imaging. Tortorella C, Codella M, Rocca MA, **Gasperini C**, Capra R, Bastianello S, Filippi M. J Neurol 1999; 246 (8): 689-92.

(I.F. 3.8)

46. T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis.

Ristori G, Montesperelli C, **Gasperini C**, Battistini L, Borsellino G, Buttinelli C, Cannoni S, Perna A, Pozzilli C, Salvetti M.

J Neuroimmunol 1999; 99 (1):91-6.

(I.F. 2.6)

47. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta -1b.

Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, Di Marco P, **Gasperini C**, Fieschi C, Dianzani F.

J Neurol Sci. 1999; 168 (2): 131-6.

(I.F. 5.98)

48. Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images.

Rovaris M, Barkhof F, Bastianello S, **Gasperini C**, Tubridy N, Yousry TA, Sormani MP, Viti B, Miller DH, Filippi M.

J Neurol 1999; (10): 920-5.

(I.F. 3.8)

49. Interferon Beta 1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images

Gasperini C, Pozzilli C, Bastianello S, Giugni E, Horfield MA, Koudriavtseva T, Galgani S, Paolillo A, Haggiag S, Millefiorini E, Fieschi C.

J Neurol Neurosurg Psychiatry 1999; 67 (5): 579-84

(I.F. 7.4)

50. Cumulative effect of weekly low dose of interferon beta 1a on standard and triple dose contrast enhanced MRI from multiple sclerosis patients.

Rovaris M, Capra R, Martinelli V, **Gasperini C**, Prandini F, Pozzilli C, Comi G, Filippi M.

J Neurol Sci 1999; 171 (2): 130-4.

(I.F. 5.98)

51. Interscanner variation in brain MR lesion load measurement in multiple sclerosis using conventional spin-echo rapid relaxation-enhanced, and fast FLAIR sequences.

Filippi M, Rocca MA, **Gasperini C**, Sormani MP, Bastianello S, Horsfield MA, Pozzilli C, Comi G.

AJNR. 1999; 20 (1):133-7.

(I.F. 3.6)

2000

52. Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study.

Bagnato F, Tancredi A, Richert N, **Gasperini C**, Bastianello S, Bash C, McFarland H, Pozzilli C, Frank JA.

Multiple Sclerosis 2000; 6(1):43-9.

(I.F. 4.84)

53. The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement.

Molyneaux PD, Miller DH, Filippi M, Yousry T, Kappos L, **Gasperini C**, Ader HJ, Barkhoff F.

J Neurol. 2000; 247(1): 34-40.

(I.F. 3.8)

54. Brain atrophy in relapsing remitting multiple sclerosis: relationship with "black holes", disease duration and clinical disability.

Paolillo A, Pozzilli C, **Gasperini C**, Giugni E, Mainero C, Giuliani S, Tomassini V, Millefiorini E, Bastianello S.

J Neurol Sci. 2000; 174(2): 85-91.

(I.F. 5.98)

55. Evidence for a role of gammadelta T cells in demyelinating diseases as determined by activation states and response of lipid antigens.

Borsellino G, Koul O, Placido R, Tramonti D, Luchetti D, Galgani S, Salvetti M, **Gasperini C**, Ristori G, Bonetti B, Bach S, Cipriani B, Battistini L.

J Neuroimmunology 2000; 107(2): 124-9.

(I.F. 2.6)

56. MRI of spinal cord in MS.

Bastianello S, Paolillo A, Giugni E, Giuliani S, Evangelisti G, Luccichenti G, Angeloni U, Colonnese C, Salvetti M, **Gasperini C**, Pozzilli C, Fieschi C.

J Neurovirol 2000; Suppl 2: S130-3.

(I.F. 3.2)

57. Antinuclear antibodies and responses to IFN beta-1a treatment in relapsing remitting multiple sclerosis.

Ciccarelli O, Bagnato F, Mainero C, Salvetti M, Paolillo A, **Gasperini C**, Bastianello S, Pozzilli C.

Mult. Scler. 2000; 6(3): 137-9.

(I.F. 4.84)

58. A comparison of the sensitivity of MRI after double-triple dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis.

Gasperini C, Paolillo A, Rovaris M, Yousry TA, Capra R, Bastianello S, Filippi M.

Magn Reson Imaging 2000; 18(6): 761-3.

(I.F. 3.6)

59. Myelin basic protein intramolecular spreading without progression in a patient with multiple sclerosis.

Ristori G, Giubilei F, Giunti D, Perna A, **Gasperini C**, Buttinelli C, Salvetti M, Uccelli A.

J Neuroimmunology. 2000; 110(1-2): 240-3.

(I.F. 2.6)

60. Serial gadolinium DTPA of spinal cord MRI in multiple sclerosis: triple vs single dose.

Yousry I, Filippi M, Walther E, **Gasperini C**, Capra R, Yousry TA.

Magn Reson Imaging. 2000; 18(9): 1183-6.

(I.F. 3.6)

2001

61. Intra-observer inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis.

Gasperini C, Rovaris M, Sormani MP, Bastianello S, Pozzilli C, Comi G, Filippi M.

Mult Scler 2000; 7(1):27-31

(I.F. 4.84)

62. Topimaratate relieves idiopathic and symptomatic trigeminal neuralgia.

Solaro C, Uccelli MM, Bricchetto G, **Gasperini C**, Mancardi G.

J Pain Symptom Manage 2001; 21(5):367-8.

(I.F. 3.2)

63. Differential diagnosis in multiple sclerosis.

Gasperini C.

Neurol Scien. 2001; 22:93-7.

(I.F. 2.28)

2002

64. Monthly corticosteroids decrease neutralizing antibodies to interferon beta 1b: a randomized trial in multiple sclerosis.

Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomasini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dalkhe F, **Gasperini C.**

J Neurol 2002; 249:50-56.

(I.F. 3.8)

65. MRI brain volume changes in relapsing multiple sclerosis patients treated with Interferon Beta 1a.

Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.

Mult Scler. 2002; 8(2): 119-23.

(I.F. 4.84)

66. A one year study on the pharmacodynamic profile of Interferon Beta 1a in MS.

Bagnato F, Pozzilli C, Scagnolari C, Bellomi F, Pasqualetti P, **Gasperini C**, Millefiorini E, Galgani S, Spadaro M, Antonelli G.

Neurology 2002; 58(9):1409-11.

(I.F. 7.6)

67. . Proteolytic blance in patients with multiple sclerosis durino Interferon Beta treatment.

Giannelli G, De Marzo A, Scagnolari C, Bergamini C, Fransvea E, Bagnato F, Bellomi F, Millefiorini E, **Gasperini C**, Antonaci S, Antonelli G.

J Interferon Cytokine Res. 2002; 22(6): 689-92.

(I.F. 2.4)

68. Home based management multiple sclerosis: results of a randomised controlled trial.
Pozzilli C, Brunetti M, Amicosante AM, **Gasperini C**, Ristori G, Palmisano L, Battaglia M.
J Neurol, Neurosurg, Psychiatry 2002; 73(3):250-5.

(I.F. 7.4)

69. A 6 years clinical and MRI follow-up study of patients with relapsing remitting MS treated with Interferon Beta.

Paolillo A, Pozzilli C, Giugni E, Tomassini V, **Gasperini C**, Fiorelli M, Maniero C, Horsfield M, Galgani S, Bastianello S, Pozzilli C.

Eur. J Neurol 2002; 9(6): 645-55.

(I.F. 3.9)

2003

70. 'Gender gap' in multiple sclerosis: magnetic resonance imaging evidence.

Pozzilli C, Tomassini V, Marinelli F, Paolillo A, **Gasperini C**, Bastianello S. Eur J Neurol 2003; 10(1):95-7

(I.F. 3.9)

71. CD8+ T cells from patients with acute multiple sclerosis displays selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1.

Battistini L, Piccio L, Rossi B, Bach S, Galgani S, **Gasperini C**, Ottoboni L, Ciabibi D, Caramia MD, Bernardi G, Laudanna C, Scarpini E, McEver RP, Butcher EC, Borsellino G, Constantin G.

Blood 2003; 101: 4775-82.

(I.F. 15.1)

72. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years.

Bellomi F, Scagnolari C, Tomassini V, **Gasperini C**, Paolillo A, Pozzilli C, Antonelli G.

J Neurol. Sci. 2003; 215:3-8.

(I.F. 5.98)

2004

73. Relationship between emotional stress in caregivers and health status in person with MS.

Pozzilli C, Palmisano L, Maniero C, Tomassini V, Marinelli F, Ristori G, **Gasperini C**, Fabiani M, Battaglia MA.

Mult Scler. 2004; 10: 442-6.

(I.F. 4.84)

74. PaIMS study group. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study.

Solaro C, Bricchetto G, Amato MP, Cocco E, Colombo B, D'Aleo G, **Gasperini C**, Ghezzi A, Martinelli V, Milanese C, Patti F, Trojano M, Verdun E, Mancardi GL,

Neurology 2004;14:919-21.

(I.F. 7.6)

2005

75. The glycopeptide CSF114 (GLc) detects serum antibodies in multiple sclerosis
Lolli F, Mazzanti B, Pazzagli M, Peroni E, Alcaro MC, Sabatino G, Lanzillo R, Brescia Morra V, Santoro L, **Gasparini C**, Galgani S, D'Elios MM, Zipoli V, Sotgiu S, Pugliatti M, Rovero P, Chelli M, Papini AM.
J Neuroimmunol. 2005; 167 (1-2): 131-7
(I.F. 2.6)

2006

76. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.
Tomassini V, Paolillo A, Russo P, Prosperini L, **Gasparini C**, Antonelli G, Bastianello S, Pozzilli C.
J Neurol. 2006 ; 253 (3): 287-93
(I.F. 3.8)

2007

77. Alexithymia in multiple sclerosis: relationship with fatigue and depression.
Bodini B, Mandarelli G, Tomassini V, Tarsitani L, Pestalozza I, **Gasparini C**, Lenzi GL, Cancheri P, Pozzilli C. Acta Neurol Scand. 2007: Dec 19.
(I.F. 3.1)

2008

78. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A, Durastanti V, **Gasparini C**, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E, CoSa study Group.
Clin Neuropharmacol. 2008 May-Jun;31(3):167-72.
(I.F. 2)

79. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N, Filippi M, Hawkins C; 9011 study group.
J Neurol Sci. 2008 Mar 15;266(1-2):44-50.
(I.F. 5.98)

80. Early relapses after the first dose of Natalizumab in active multiple sclerosis patients.
Centonze D, Furlan R, **Gasparini C**, Salvetti M, Battistini L.
Multiple Sclerosis 2008 Sep 14 (8) : 1137-1138
(I.F. 4.84)

81. Emerging oral drugs for multiple sclerosis.
Gasparini C, Cefaro LA, Borriello G, Tosto G, Prosperini L, Pozzilli C.
Expert Opin. Emerg Drugs. 2008 Sep 13(3): 465-77. Review

(I.F. 3)

2009

82. Cognitive impairment and its relation with disease measures in mildly disabled patients with RRMS. Baseline results from COGIMUS Study.

COGIMUS study group.

Multiple Sclerosis 2009 Jul 15 (7): 779-88

(I.F. 4.84)

83. Long lasting response of chronic lymphocytic leukemia and multiple sclerosis in a patient treated with oral fludarabine alone.

D'Arena G, **Gasparini C**, Cascavilla N.

Tumori 2009 May-Jun 95 (3): 406-7

(I.F. 1.23)

84. New oral drugs for multiple sclerosis.

Gasparini C, Ruggieri S.

Neurol Sci. 2009 Oct;30 Suppl 2:S179-83. Review

(I.F. 2.28)

85. Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study

Sbardella E, Tomassini V, **Gasparini C**, Bellomi F, Cefaro LA, Morra VB, Antonelli G, Pozzilli C.

BMC Neurol. 2009 Oct 13;9:54.

(I.F. 2.5)

86. Effect of glatiramer acetate on conversion to clinically isolated syndrome (preCISe study: a randomised double – blind, placebo – controlled trial.

Comi G, Martinelli V, Rodegher M, Momiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group

Lancet. 2009 Oct 31;374(9700):1503-11.

(I.F. 53.2)

87. Validation of the Dymus questionnaire for the assessment of dysphagia in multiple sclerosis.

Bergamaschi R, Rezzani C, Minguzzi S, Amato MP, Patti F, Marrosu MG, Bonavita S, Grasso MG, Ghezzi A, Rottoli M, **Gasparini C**, Restivo D, Maimone D, Rossi P, Stromillo ML, Montomoli C, Solaro C, Group D.

Funct Neurol. 2009 Jul-Sep;24(3):159-62. (I.F. 1.9)

2010

88. Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets.

Gasparini C, Ruggieri S, Pozzilli C.

Ther Clin Risk Manag. 2010 Sep 7;6:391-9.

(I.F. 2)

89. The prevalence of multiple sclerosis in central Italy.

Millefiorini E, Cortese A, Di Rezze S, Barletta G, Bellantonio P, Batocchi AP, Di Battista G, Fiore S, **Gasparini C**, Grasso MG, Koudriatseva T, Totaro R, Durastanti V.

Mult Scler. 2010 Dec;16(12):1432-6

(I.F. 4.84)

90. Rapid benefits of a new formulation of subcutaneous interferon beta – 1a in relapsing remitting multiple sclerosis

De Stefano N, Curtin F, Stubinski B, Blevins G, Drulovic J, Issard D, Shotekov P, **Gasparini C**; IMPROVE Study Investigators.

Mult Scler. 2010 Jul;16(7):888-92.

(I.F. 4.84)

91. Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group. Effects of immunomodulatory treatment with subcutaneous interferon beta -1a on cognitive decline in mildly disabled patients with relapsing remitting multiple sclerosis.

Mult Scler. 2010 Jan;16(1):68-77. **(I.F.4.84)**

2011

92. Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis

De Stefano N, Stromillo ML, Rossi F, Battaglini M, Giorgio A, Portaccio E, Hakiki B, Malentacchi G, **Gasparini C**, Santangelo M, Bartolozzi ML, Sormani MP, Federico A, Amato MP.

PLoS One. 2011 Apr 29;6(4)

(I.F. 3.5)

93. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNitive Impairment in MULTiple Sclerosis) study.

Patti F, Amato M, Trojano M, Bastianello S, Tola M, Picconi O, Cilia S, Cottone S, Centonze D, **Gasparini C**.

Mult Scler. 2011 Apr 18.

(I.F. 4.84)

94. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, **Gasparini C**, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P; the Sativex Spasticity Study Group.

Eur J Neurol. 2011 1468-1331.

(I.F. 3.8)

95. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; FORTE Study Group.

Ann Neurol. 2011 Jan;69(1):75-82.

(I.F. 9.89)

96. T regulatory cells are markers of disease activity in multiple sclerosis patients

Dalla Libera D, Di Mitri D, Bergami A, Centonze D, **Gasparini C**, Grasso MG, Galgani S, Martinelli V, Comi G, Avolio C, Martino G, Borsellino G, Sallusto F, Battistini L, Furlan R.

PLoS One. 2011;6(6):e21386

(I.F. 3.5)

97. Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis.

Sbardella E, Tomassini V, Stromillo M, Filippini N, Battaglini M, Ruggieri S, Ausili Cefaro L, Raz E, **Gasperini C**, Sormani M, Pantano P, Pozzilli C, De Stefano N.

Mult Scler. 2011 Jul 5.

(I.F. 4.84)

98. Impaired cortical deactivation during hand movement in the relapsing phase of multiple sclerosis: a cross-sectional and longitudinal fMRI study.

Pantano P, Bernardi S, Tinelli E, Pontecorvo S, Lenzi D, Raz E, Tona F, **Gasperini C**, Pozzilli C.

Mult Scler. 2011 Jun 15.

(I.F. 4.84)

99. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

Prosperini L, Gianni C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, **Gasperini C**.

Mult Scler. 2011

(I.F. 4.84)

100. Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study

De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, **Gasperini C**.

J Neurol Sci. 2011

(I.F. 5.98)

101. Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β -1a in the COGNitive Impairment in Multiple Sclerosis (COGIMUS) study

Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, Luccichenti G, Quarantelli M, Picconi O, Patti F; COGIMUS study group.

BMC Neurol. 2011 Oct 14;11:125.

(I.F. 2.5)

102. [Randomized trial of oral teriflunomide for relapsing multiple sclerosis.](#)

O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group.

N Engl J Med. 2011

(I.F. 13.5)

103. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.

Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A,

Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, **Gasperini C**, Rodegher M, Straffi L, Ponzio M, Comi G; Italian Mitoxantrone Group
Neurology. 2011
(I.F. 7.6)

104. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
Mancardi G, Sormani M, Di Gioia M, Vuolo L, Gualandi F, Amato M, Capello E, Currò D, Uccelli A, Bertolotto A, **Gasperini C**, Lugaresi A, Merelli E, Meucci G, Motti L, Tola M, Scarpini E, Repice A, Massacesi L, Saccardi R.
Mult Scler. 2011.
(I.F. 4.84)

105. Emerging oral drugs for relapsing-remitting multiple sclerosis.
Gasperini C, Ruggieri S.
Expert Opin Emerg Drugs. 2011 Dec;16(4):697-712.
(I.F. 3)

2012

106. A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.
Annovazzi P, Tomassini V, Bodini B, Boffa L, Calabrese M, Cocco E, Cordioli C, De Luca G, Frisullo G, Gallo A, Malucchi S, Paolicelli D, Pesci I, Radaelli M, Ragonese P, Roccatagliata L, Tortorella C, Vercellino M, Zipoli V, **Gasperini C**, Rodegher M, Solaro C.
Neurol Sci. 2013.
(I.F. 2.28)

107 Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
Gasperini C, Ruggieri S.
Drug Des Devel Ther. 2012.
(I.F. 2.8)

2013

108. Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis.
Giorgio A, Battaglini M, Rocca MA, De Leucio A, Absinta M, van Schijndel R, Rovira A, Tintore M, Chard D, Ciccarelli O, Enzinger C, **Gasperini C**, Frederiksen J, Filippi M, Barkhof F, De Stefano N; MAGNIMS Study Group.
Neurology. 2013
(I.F. 7.6)

109. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi

F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M; Italian MS Study Group (Ghezzi A, Zaffaroni M, Bianchi A, Pozzilli C, Prosperini L, Borriello G, Filippi M, Moiola L, Gerevini S, Rocca MA, Martinelli V, Comi G, Brescia-Morra V, Lanzillo R, Grimaldi LM, Bucello S, Lus G, Rinaldi F, Gallo P, Trojano M, Provinciali L, Pucci E, Bortolon F, Capra R, Coniglio G, **Gasperini C**, Lugaresi A, Pietrolongo E, Farina D, di Ioia M, Milani N, Rottoli MR, Sarchielli P).

Mult Scler. 2013.

(I.F. 4.84)

110. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMPO) Trial Group (Maida E, Auff E, Fazekas F, Berger T, Bhan V, Bouchard JP, Duquette P, Freedman M, Grand'maison F, Kremenchutzky M, Bourque C, Marrie RA, Melanson M, Patry D, O'Connor P, Oger J, Stefanelli M, Jacques F, Venegas P, Miranda M, Barrientos N, Tenhamm E, Gloger S, Rohde G, Mares J, Frederiksen J, Stenager E, Haldre S, Gross-Paju K, Elovaara I, Sumelahti ML, Erälinna JP, Erälinna JP, Färkkilä M, Harno H, Reunanen M, Jolma T, Confavreux C, Camu W, Clavelou P, Magy L, Debouverie M, Edan G, Lebrun-Frenay C, Moreau T, Pelletier J, Roullet E, Alamowitch S, Clanet M, Hautecoeur P, Damier P, Rumbach L, Chan A, Schimrigk S, Haas J, Lensch E, Diener H, Limmroth V, Anders D, Berghoff M, Oschmann P, Stangel M, Berghoff M, Frese A, Kiefer R, Marziniak M, Zettl U, Stark E, Jendroska K, Reifschneider G, Amato MP, Comi G, Cosi V, Gallo P, **Gasperini C**, Ghezzi A, Trojano M, Pozzilli C, Montanari E, Zwanikken CP, Jongen PJ, Centrum MS, Van Munster ET, Hupperts RM, Anten B, Sanders EA, Celius E, Hovdal H, Krogseth SB, Kozubski W, Kwiecinski H, Czlonkowska A, Stelmasiak Z, Selmaj K, Hasiec T, Fryze W, Drozdowski W, Kochanowicz J, Cunha L, De Sá J, Harrington Sena A, Odinak M, Skoromets A, Gusev E, Boiko A, Lashch N, Stolyarov I, Belova A, Malkova N, Doronin B, Yakupov E, Brundin L, Hillert J, Kappos L, Karabudak R, Irkec C, Idiman E, Turan O, Efendi H, Gedizlioglu M, Buchakchyyska N, Goloborodko A, Ipatov A, Kobets S, Lebedynets V, Moskovko S, Yushchenko OI, Sanotskyy Y, Smolanka V, Yavorskaya V, Bates D, Evangelou N, Hawkins C, McLean B, O'Riordan J, Price S, Turner B, Barnes D, Zajicek J, Honeycutt W, Khan O, Spikol L, Stevens J).

Mult Scler. 2013.

(I.F. 4.84)

111. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis.

Chiurciu V, Cencioni MT, Bisicchia E, De Bardi M, **Gasperini C**, Borsellino G, Centonze D, Battistini L, Maccarrone M.

Ann Neurol 2013 May;73(5):626-36.

(I.F. 9.89)

112. Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod.

Gasperini C, Ruggieri S, Mancinelli CR, Pozzilli C.

Ther Clin Risk Manag. 2013;9:73-85.

(I.F. 2)

113. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis.

Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, **Gasperini C**, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F,

Battistini L.
PLoS Pathog. 2013.
(I.F. 7.6)

114. Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome.

Stromillo ML, Giorgio A, Rossi F, Battaglini M, Hakiki B, Malentacchi G, Santangelo M, **Gasparini C**, Bartolozzi ML, Portaccio E, Amato MP, De Stefano N.

Neurology. 2013

(I.F. 7.6)

115. Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire).

Solaro C, Rezzani C, Trabucco E, Amato MP, Zipoli V, Portaccio E, Giannini M, Patti F, D'Amico E, Frau J, Loreface L, Bonavita S, Della Corte M, Grasso MG, Finamore L, Ghezzi A, Annovazzi P, Rottoli M, **Gasparini C**, Restivo D, Maimone D, Rossi P, Stromillo ML, Bergamaschi R.

J Neurol Sci. 2013.

(I.F. 5.98)

116. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration.

Kearney H, Rocca MA, Valsasina P, Balk L, Sastre-Garriga J, Reinhardt J, Ruggieri S, Rovira A, Stippich C, Kappos L, Sprenger T, Tortorella P, Rovaris M, **Gasparini C**, Montalban X, Geurts JJ, Polman CH, Barkhof F, Filippi M, Altmann DR, Ciccarelli O, Miller DH, Chard DT.

Mult Scler. 2014.

(I.F. 4.84)

117. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.

Gasparini C, Haggiag S, Ruggieri S.

Expert Opin Investig Drugs. 2013

(I.F.3.9)

118. Subcutaneous interferon β -1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.

Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, Cottone S, Plant A, Picconi O; COGIMUS Study Group (Patti F, Lo S, Messina S, Vecchio R, Maimone D, **Gasparini C**, Orefice G, Brescia-Morra V, Florio C, Amato MP, Goretti B, Portaccio E, Zipoli V, Bertolotto A, Bramanti P, Sessa E, Centonze D, Cottone S, Salemi G, Falcini M, Gallo P, Perini P, Gigli GL, Giuliani G, Grimaldi LM, Murri L, Lugaresi A, Monaco F, Montanari E, Motti L, Neri G, Paciello M, Provinciali L, Ragno M, Rosati G, Ruggieri S, Tola MR, Caniatti L, Tonali P, Batocchi AP, Trojano M, Di Monte E, De Caro MF, Ghezzi A, Zaffaroni M, Zolo P, Zorzon M, Scarpini E, Durelli L, Carolei A, Totaro R, Spitaleri D, Tartaglione A).

PLoS One. 2013

(I.F. 3.5)

119. Efficacy and safety of laquinimod in multiple sclerosis: current status.

Haggiag S, Ruggieri S, **Gasparini C**.

Ther Adv Neurol Disord. 2013 Nov;6(6):343-52.

(I.F. 4.7)

2014

120. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS.

Ristori G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, Cecconi P, Lanzillo R, Quarantelli M, Buttinelli C, **Gasparini C**, Frontoni M, Coarelli G, Caputo D, Bresciamorra V, Vanacore N, Pozzilli C, Salvetti M.

Neurology. 2014 Jan 7;82(1):41-8.

(I.F. 7.6)

121. CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes.

Camperio C, Muscolini M, Volpe E, Di Mitri D, Mechelli R, Buscarinu MC, Ruggieri S, Piccolella E, Salvetti M, **Gasparini C**, Battistini L, Tuosto L.

Immunol Lett. 2014 Mar-Apr;158(1-2):134-42.

(I.F. 2.9)

122. From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study.

Prosperini L, Mancinelli CR, Pozzilli C, Grasso MG, Clemenzi A, Collorone S, Pontecorvo S, Francia A, Villani V, Koudriavtseva T, Buttari F, Centonze D, Di Battista G, Frisullo G, Galgani S, **Gasparini C**.

Eur Neurol. 2014

(I.F. 3.9)

123. Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.

Frisullo G, Calabrese M, Tortorella C, Paolicelli D, Ragonese P, Annovazzi P, Radaelli M, Malucchi S, Gallo A, Tomassini V, Nociti V, D'Onghia M, Lo Re V, Rodegher M, Solaro C, **Gasparini C**.

Mult Scler. 2014

(I.F. 4.84)

124. Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis.

Ruggieri S, Tortorella C, **Gasparini C**.

Ther Clin Risk Manag. 2014 Review

(I.F. 2)

125. Serum lactate as a novel potential biomarker in multiple sclerosis.

Amorini AM, Nociti V, Petzold A, **Gasparini C**, Quartuccio E, Lazzarino G, Di Pietro V, Belli A, Signoretti S, Vagnozzi R, Lazzarino G, Tavazzi B.

Biochim Biophys Acta. 2014

(I.F. 5.34)

126. MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.

Serana F, Imberti L, Amato MP, Comi G, **Gasperini C**, Ghezzi A, Martinelli V, Provinciali L, Rottoli MR, Sotgiu S, Stecchi S, Vecchio M, Zaffaroni M, Cordioli C, Capra R. PLoS One. 2014 (I.F. 3.5)

127. Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.

Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, **Gasperini C**, Florio C, Pucci E, Maddestra M, Spitaleri D, Lus G, Ardito B, Farina D, Rossi M, Di Carmine C, Altobelli E, Maccarone B, Casalena A, De Luca G, Travaglini D, Di Ioia M, Di Tommaso V, Fantozzi R, Ruggieri S, Provinciali L, De Riso S, Mundi C, Fuiani A, Galgani S, Ruggieri S, Maniscalco GT, Giuliani G, Cartechini E, Petretta V, Fratta M, Alfieri G, Gatto M, Carolei A; Natalizumab Long-Term Treatment Study group. Int J Immunopathol Pharmacol. 2014

128. Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy's Adherence, Hospital Reliability's Perception, and Services Provided Quality.

Di Battista G, Bertolotto A, **Gasperini C**, Ghezzi A, Maimone D, Solaro C.

Mult Scler Int. 2014;2014:752318.

(I.F. 0.7)

2015

129. De Giglio L, **Gasperini C**, Tortorella C, Trojano M, Pozzilli C.

Natalizumab discontinuation and disease restart in pregnancy: a case series.

Acta Neurol Scand. 2015

(I.F. 3.1)

130. Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.

Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, **Gasperini C**, Galgani S, Solaro C, Centonze D, Bertolotto A, Pozzilli C, Ghezzi A.

Mult Scler. 2015 Feb 19.

(I.F. 4.84)

131. T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis.

Ruocco G, Rossi S, Motta C, Macchiarulo G, Barbieri F, De Bardi M, Borsellino G, Finardi A, Grasso MG, Ruggieri S, **Gasperini C**, Furlan R, Centonze D, Battistini L, Volpe E.

Clin Sci (Lond). 2015 Aug 1;129(4):291-303.

(I.F. 5.38)

132. Visual pathway neurodegeneration winged by mitochondrial dysfunction.

Petzold A, Nijland PG, Balk LJ, Amorini AM, Lazzarino G, Wattjes MP, **Gasperini C**, van der Valk P, Tavazzi B, Lazzarino G, van Horssen J.

Ann Clin Transl Neurol. 2015 Feb;2(2):140-50.

(I.F. 4.6)

133. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. Cencioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, Ruggieri S, **Gasperini C**, Centonze D, Barilá D, Battistini L, Volpe E.

Cell Death Dis. 2015 May 7;6:e1741.

(I.F. 6)

134. Hupperts R, Lycke J, Short C, **Gasparini C**, McNeill M, Medori R, Tofil-Kaluza A, Hovenden M, Mehta LR, Elkins J.
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. *Mult Scler.* 2015 Apr 28
(I.F. 4.84)

135. The p38 MAPK cascade modulates TH17 differentiation and functionality in Multiple Sclerosis.
Di Mitri D, Sambucci M, Loiarro M, De Bardi M, Volpe E, Cencioni MT, **Gasparini C**, Centonze D, Sette C, Akbar AN, Borsellino G, Battistini L.
Immunology. 2015
(I.F. 3.35)

2016.

136. MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis : MAGNIMS consensus guidelines
Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, **Gasparini C**, Palace J, Reich DS, Banwell B, Montalban X, Barkhof
Lancet Neurol. 2016
(I.F. 28)

137. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.
Neurology. 2016
(I.F. 7.6)

138. Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems.
Bargagli AM, Colais P, Agabiti N, Mayer F, Buttari F, Centonze D, Di Folco M, Filippini G, Francia A, Galgani S, **Gasparini C**, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Davoli M.
J Neurol. 2016.
(I.F. 3.8)

139. A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.
Montanari E, Rottoli M, Maimone D, Confalonieri P, Plewnia K, Frigo M, Francia A, Pala A, Losignore NA, Ragonese P, Veneziano. A POSIDONIA study group
J Neurol Sci. 2016.
(I.F. 5.98)

140. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M,

Francia A, Gajofatto A, **Gasparini C**, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group
J Neurol Neurosurg Psychiatry. 2016

(I.F.7.4)

141. Assessing response to interferon Beta in a multicenter dataset of patients with MS
Sormani MP, **Gasparini C**, Romeo M, Rio J, Calabrese M, Cocco E, Enzinger C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group.

Neurology. 2016 Jul 12;87(2):134-40.

(I.F. 7.6)

142. Prolonged release fampridine treatment improved subject reported impact of multiple sclerosis : Item-level analysis of the MSIS-29

Gasparini C, Hupperts R, Lycke J, Short C, McNeill M, Zhong J, Mehta LR.

J Neurol Sci. 2016 Nov 15;370:123-131

(I.F. 5.98)

143. Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis

Lazzarino G, Amorini AM, Petzold A, **Gasparini C**, Ruggieri S, Quartuccio ME, Lazzarino G, Di Stasio E, Tavazzi B.

Mol Neurobiol. 2017 Nov;54(9):7520-7533.

(I.F. 5)

144. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, **Gasparini C**, Millefiorini E, Mirabella M, Pozzilli C.

J Neurol. 2016.

(I.F. 3.8)

145. Dysregulated Homeostasis of Acetylcholine levels in immune cells of RR-multiple sclerosis patients.

Di Bari M, Reale M, Di Nicola M, Orlando V, Galizia S, Porfilio I, Costantini E, D'Angelo C, Ruggieri S, Biagioni S, **Gasparini C** and Tata AM.

Int. J. Mol Sci 2016. 17(12)

(I.F. 3.8)

2017

146. No evidence of beneficial effect of plasmapheresis in natalizumab-associated PML

Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D, **Italian PML study group.**

Neurology 2017.

(I.F. 7.6)

147. A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band.

Ferraro D, Franciotta D, Bedin R, Solaro C, Cocco C, Santangelo M, Immovilli P, Gajofatto A, Calbrese M, Di Filippo M, Orlandi R, Simone AM, Vitetta F, Capello E, Giunti D, Murialdo A, Frau J, Mariotto S, Gallina A, **Gasparini C**, Sola P. RIREMS group (Rising Italian researchers in Multiple Sclerosis).

J Neurol 2017.

(I.F. 3.8)

148. Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.

Tortorella C, Dirienzo V, Ruggieri M, Zoccolella S, Mastropasqua M, D'Onghia M, Paolicelli D, Cuonzo FD, **Gasparini C**, Trojano M.

Mult scler. 2017

(I.F. 4.84)

149. A Comprehensive Review on Copemyl®.

Annovazzi P, Bertolotto A, Brescia Morra V, **Gasparini C**, Montanari E, Navarra P, Patti F, Sormani MP, Ghezzi A.

Neurol Ther. 2017

(I.F. 1.1)

150. Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).

Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB, Brescia Morra V, Costantino G, Cavalla P, Centonze D, Comi G, Cottone S, Danni MC, Francia A, Gajofatto A, **Gasparini C**, Zaffaroni M, Petrucci L, Signoriello E, Maniscalco GT, Spinicci G, Matta M, Mirabella M, Pedà G, Castelli L, Rovaris M, Sessa E, Spitaleri D, Paolicelli D, Granata A, Zappia M, Patti F; SA.FE. study group.

PLoS One. 2017

(I.F. 3.5)

151. Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy.

Colais P, Agabiti N, Davoli M, Buttari F, Centonze D, De Fino C, Di Folco M, Filippini G, Francia A, Galgani S, **Gasparini C**, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Bargagli A; Multiple Sclerosis Study Group, Lazio Region.

Neuroepidemiology. 2017

(I.F. 3.7)

152. Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis.

Ruggieri S, Tortorella C, **Gasparini C**.

Expert Rev Neurother. 2017 Nov;17(11):1081-1089.

(I.F. 3.7)

153. Modulation of P2X7 Receptor during Inflammation in Multiple Sclerosis.

Amadio S, Parisi C, Piras E, Fabbri P, Apolloni S, Montilli C, Luchetti S, Ruggieri S, **Gasparini C**, Laghi-Pasini F, Battistini L, Volonté C.

2018.

154. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.

Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, **Gasparini C**, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA.

Lancet Neurol 2018 Feb;17(2):133-142.

(I.F. 28)

155. Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.

Hagens MH, Burggraaff J, Kilsdonk ID, Ruggieri S, Collorone S, Cortese R, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Wuerfel J, Ciccarelli O, **Gasparini C**, Lukas C, Rovira A, Barkhof F, Wattjes MP; MAGNIMS Study Group.

Mult Scler. 2018

(I.F. 4.84)

156. Deep grey matter volume loss drives disability worsening in multiple sclerosis.

Eshaghi A, Prados F, Brownlee W, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, **Gasparini C**, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group.

Ann Neurol 2018 Feb;83(2):210-222.

(I.F. 9.89)

157. Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation.

Reale M, Costantini E, Di Nicola M, D'Angelo C, Franchi S, D'Aurora M, Di Bari M, Orlando V, Galizia S, Ruggieri S, Stuppia L, **Gasparini C**, Tata AM, Gatta V.

Sci Rep. 2018 Jan 22;8(1):1319.

(I.F. 4.1)

158. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018
(I.F. 7.6)

159. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018
(I.F. 7.6)

160. FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis.

Sambucci M, Gargano F, De Rosa V, De Bardi M, Picozza M, Placido R, Ruggieri S, Capone A, **Gasperini C**, Matarese G, Battistini L, Borsellino G.

Sci Rep. 2018 Feb 27;8(1):3674

(I.F. 4.1)

161. The current role of MRI in differentiating multiple sclerosis from its imaging mimics
Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, **Gasperini C**, Sastre-Garriga J, Evangelou N, Palace J; MAGNIMS study group.

Nat Rev Neurol. 2018 Apr;14(4):199-213.

(I.F. 20.2)

162. A multicentRE observational analysis of PERSISTENCE to Treatment in the new multiple sclerosis era: the RESPECT study.

Lanzillo R, Prosperini L, **Gasperini C**, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group.

J Neurol. 2018

(I.F. 3.8)

163. Progression of regional grey matter atrophy in multiple sclerosis.

Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M, Tur C, De Angelis F, Cawley N, Brownlee WJ, De Stefano N, Laura Stromillo M, Battaglini M, Ruggieri S, **Gasperini C**, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Geurts JJG, Vrenken H, Wottschel V, Leurs CE, Uitdehaag B, Pirpamer L, Enzinger C, Ourselin S, Gandini Wheeler-Kingshott CA, Chard D, Thompson AJ, Barkhof F, Alexander DC, Ciccarelli O; MAGNIMS study group.

Brain 2018 Jun 1;141(6):1665-1677. (I.F. 10.84)

164. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study

Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, **Gasperini C**, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M.

Neurology. 2018 Jul 10;91(2):e153-e161.

(I.F. 7.6)

165. Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.

Hagens MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Ciccarelli O, **Gasperini C**, Lukas C, Wattjes MP, Barkhof F; MAGNIMS Study Group. Neurology. 2018 Jul 17;91(3):e249-e257

(I.F. 7.6)

166. Abortion induces reactivation of inflammation in relapsing remitting multiple sclerosis

Landi D, Ragonese P, Prosperini L, Nociti V, Haggiag S, Cortese A, Fantozzi R, Pontecorvo S, Ferraro E, Buscarinu MC, Mataluni G, Monteleone F, Salvetti M, Di Battista G, Francia A, Millefiorini E, **Gasperini C**, Mirabella M, Salemi G, Boffa L, Pozzilli C, Centonze D, Marfia GA.

J Neurol Neurosurg Psychiatry. 2018 Jul 3. pii: jnnp-2018-318468.

(I.F. 7.4)

167. Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report

Galgani S, Prosperini L, Haggiag S, Tortorella C, **Gasperini C**.

J Neurol. 2018 Jul 17.

(I.F. 3.8)

168. Safety and Efficacy of Dymethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study

Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, **Gasperini C**, Haggiag S, Landi D, Marfia GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C.

CNS Drugs. 2018

(I.F. 5.5)

169. Induction Treatment Strategy in Multiple Sclerosis: A Review of Past Experiences and Future Perspectives.

Ruggieri S, Pontecorvo S, Tortorella C, **Gasperini C**.

Multiple Sclerosis and Demyelinating Disorders 2018

170. The hippocampus in multiple sclerosis.

Rocca MA, Barkhof F, De Luca J, Frisén J, Geurts JJG, Hulst HE, Sastre-Garriga J, Filippi M; MAGNIMS Study Group

Lancet Neurol. 2018 Oct;17(10):918-926. Review **(I.F. 28)**

171. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.

Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S; Italian PML Group.

J Neurol Neurosurg Psychiatry. 2018 **(I.F. 7.4)**

172. Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®.

Annovazzi P, Bertolotto A, Brescia Morra V, **Gasparini C**, Montanari E, Navarra P, Patti F, Pia Sormani M, Ghezzi A.
Neurol Ther. 2018 (**I.F. 1.1**)

173. Unravelling treatment response in multiple sclerosis: a clinical and MRI challenge
C. Gasparini, L. Prosperini, M. Tintoré, M. P. Sormani, M. Filippi, J. Rio, J. Palace, M. A. Rocca, O. Ciccarelli, F. Barkhof, J. Sastre-Garriga, H. Vrenken, J.L. Fredrekisen, T. Yousry, C. Enzinger, A. Rovira, L. Kappos, C. Pozzilli, X. Montalban, N. De Stefano.
On behalf of MAGNIMS study group.
Neurology 2018
(**I.F. 7.6**)

2019

174. How much do periventricular lesions assist in distinguishing migraine with aura from CIS?

Lapucci C, Saitta L, Bommarito G, Sormani MP, Pardini M, Bonzano L, Mancardi GL, **Gasparini C**, Giorgio A, Inglese M, De Stefano N, Roccatagliata L.
Neurology 2019

175. “No Better explanations” in multiple sclerosis diagnostic workup: A 3- yera longitudinal study

Calabrese M, **Gasparini C**, Tortorella C, Schiavi G, Frisullo G, Ragonese P, Fantozzi R, Prosperini L, Annovazzi P, Cordioli C, Di Filippo M, Ferraro D, Gajofatto A, Malucchi S, Lo Fermo S, De Luca G, Stromillo ML, Cocco E, Gallo A, Paolicelli D, Lanzillo R, Tomassini V, Pesci I, Rodegher ME, Solaro C; RIREMS group (Rising Italian Researchers in Multiple Sclerosis).
Neurology 2019

176. Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support

Bassi M, Cilia S, Falautano M, Grobberio M, Nicolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, **Gasparini C**, Minacapelli E, Patti F, Trojano M, Delle Fave A.
Disabil Rehabil (2019)

177. Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis Patients

Capone A, Bianco M, Ruocco G, De Bardi M, Battistini L, Ruggieri S, **Gasparini C**, Centonze D, Sette C, Volpe E.
Cells (2019)

178. Resiquimod- Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple Sclerosis.

Corsetti M, Ruocco G, Ruggieri S, **Gasparini C**, Battistini L, Volpe E.
Int J Mol Sci 2019

179. Effect of dalfampridine on information processing speed impairment in in multiple sclerosis.

De Giglio L, De Luca F, Gurreri F, Ferrante I, Prosperini L, Borriello G, Quartuccio E, **Gasparini C**, Pozzilli C.
Neurology 2019

- 180.** Lifespan normative data on rates of brain volume changes.
Battaglini M, Gentile G, Luchetti L, Giorgio A, Vrenken H, Barkhof F, Cover KS, Bakshi R, Chu R, Sormani MP, Enzinger C, Ropele S, Ciccarelli O, Wheeler-Kingshott C, Yiannakas M, Filippi M, Rocca MA, Preziosa P, Gallo A, Biseco A, Palace J, Kong Y, Horakova D, Vaneckova M, **Gasparini C**, Ruggieri S, De Stefano N; MAGNIMS Study Group.
Neurobiol Aging 2019
- 181.** CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis.
Kunkl M, Sambucci M, Ruggieri S, Amormino C, Tortorella C, **Gasparini C**, Battistini L, Tuosto L.
Cells 2019
- 183.** Single-subject structural cortical networks in clinically isolated syndrome.
Collorone S, Prados F, Hagens MH, Tur C, Kanber B, Sudre CH, Lukas C, **Gasparini C**, Oreja-Guevara C, Andelova M, Ciccarelli O, Wattjes MP, Ourselin S, Altmann DR, Tijms BM, Barkhof F, Toosy AT; MAGNIMS Study Group.
Mult Scler. 2019
- 184.** The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological well-being.
Bassi M, Cilia S, Falautano M, Grobberio M, Negri L, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, **Gasparini C**, Minacapelli E, Patti F, Trojano M, Delle Fave A.
Health Soc Care Community. 2020
- 185.** Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.
Paolicelli D, Lucisano G, Manni A, Avolio C, Bonavita S, Brescia Morra V, Capobianco M, Cocco E, Conte A, De Luca G, De Robertis F, **Gasparini C**, Gatto M, Gazzola P, Lus G, Iaffaldano A, Iaffaldano P, Maimone D, Mallucci G, Maniscalco GT, Marfia GA, Patti F, Pesci I, Pozzilli C, Rovaris M, Salemi G, Salvetti M, Spitaleri D, Totaro R, Zaffaroni M, Comi G, Amato MP, Trojano M; Italian MS Register.
J Neurol. 2019
- 186.** SVM recursive feature elimination analyses of structural brain MRI predicts near-term relapses in patients with clinically isolated syndromes suggestive of multiple sclerosis.
Wotschel V, Chard DT, Enzinger C, Filippi M, Frederiksen JL, **Gasparini C**, Giorgio A, Rocca MA, Rovira A, De Stefano N, Tintoré M, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group and the EuroPOND consortium.
Neuroimage Clin. 2019
- 187.** Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction.
Kooij G, Derada Troletti C, Leuti A, Norris PC, Riley I, Albanese M, Ruggieri S, Libreros S, van der Pol SMA, van Het Hof B, Schell Y, Guerrero G, Buttari F, Mercuri NB, Centonze D, **Gasparini C**, Battistini L, de Vries HE, Serhan CN, Chiurchiù V.
Haematologica. 2019

188. Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial
Prosperini L, Castelli L, De Giglio L, Bonanno V, **Gasparini C**, Pozzilli C.
Neurotherapeutics. 2019

189. The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis.
Bassi M, Grobberio M, Negri L, Cilia S, Minacapelli E, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, Falautano M, **Gasparini C**, Patti F, Trojano M, Delle Fave A.
J Clin Psychol Med Settings. 2019

2020

190. Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study.
Prosperini L, Cortese A, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Capone F, Centonze D, De Fino C, De Pascalis D, Fantozzi R, Ferraro E, Filippi M, Galgani S, **Gasparini C**, Haggiag S, Landi D, Marfia G, Mataluni G, Millefiorini E, Mirabella M, Monteleone F, Nociti V, Pontecorvo S, Romano S, Ruggieri S, Salvetti M, Tortorella C, Zannino S, Di Battista G.
J Neurol. 2020

191. Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study.
Ferraro D, Annovazzi P, Moccia M, Lanzillo R, De Luca G, Nociti V, Fantozzi R, Paolicelli D, Ragonese P, Gajofatto A, Boffa L, Cavalla P, Lo Fermo S, Buscarinu MC, Lorefice L, Cordioli C, Calabrese M, Gallo A, Pinardi F, Tortorella C, Di Filippo M, Camera V, Maniscalco GT, Radaelli M, Buttari F, Tomassini V, Cocco E, **Gasparini C**, Solaro C; RIREMS (Rising Researchers in Multiple Sclerosis).
Mult Scler Relat Disord. 2020

192. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
Prosperini L, Mancinelli C, Haggiag S, Cordioli C, De Giglio L, De Rossi N, Galgani S, Rasia S, Ruggieri S, Tortorella C, Pozzilli C, **Gasparini C**.
J Neurol Neurosurg Psychiatry. 2020

193. Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis.
Geraldès R, Juryńczyk M, Dos Passos G, Prichler A, Chung K, Hagens M, Ruggieri S, Huerga E, Sastre-Garriga J, Enzinger C, Chard DT, Barkhof F, **Gasparini C**, Rovira A, DeLuca GC, Palace J; MAGNIMS study group.
J Neurol Neurosurg Psychiatry. 2020

194. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice.
Sastre-Garriga J, Pareto D, Battaglini M, Rocca MA, Ciccarelli O, Enzinger C, Wuerfel J, Sormani MP, Barkhof F, Yousry TA, De Stefano N, Tintoré M, Filippi M, **Gasparini C**, Kappos L, Río J, Frederiksen J, Palace J, Vrenken H, Montalban X, Rovira A; MAGNIMS study group.
Nat Rev Neurol. 2020

- 195.** Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS) Negri L, Minacapelli E, Bassi M, Cilia S, Falautano M, Grobberio M, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, **Gasparini C**, Patti F, Trojano M, Delle Fave A. *Neurol Sci.* 2020
- 196.** Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. Mantovani LG, Cozzolino P, Cortesi PA, Patti F; SA.FE. study group. *Clin Drug Investig.* 2020
- 197.** Specialized pro-resolving lipid mediators are differently altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction Kooij G, Troletti CD, Leuti A, Norris PC, Riley I, Albanese M, Ruggieri S, Libreros S, van der Pol SMA, van Het Hof B, Schell Y, Guerrero G, Buttari F, Mercuri NB, Centonze D, **Gasparini C**, Battistini L, de Vries HE, Serhan CN, Chiurchiù V. *Haematologica.* 2020 Aug;105(8):2056-2070.
- 198.** Unilateral meningitis: unusual central nervous system involvement in rheumatoid arthritis Tortorella C, Prosperini L, Sebastiani G, **Gasparini C**. *Pract Neurol.* 2020.
- 199.** Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm. Cole JH, Raffel J, Friede T, Eshaghi A, Brownlee WJ, Chard D, De Stefano N, Enzinger C, Pirpamer L, Filippi M, **Gasparini C**, Rocca MA, Rovira A, Ruggieri S, Sastre-Garriga J, Stromillo ML, Uitdehaag BMJ, Vrenken H, Barkhof F, Nicholas R, Ciccarelli O; MAGNIMS study group. *Ann Neurol.* 2020 Jul;88(1):93-105. doi:10.1002/ana.25746. Epub 2020 May 6. PMID: 32285956.
- 200.** Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review Filippi M, Preziosa P, Barkhof F, Chard DT, De Stefano N, Fox RJ, **Gasparini C**, Kappos L, Montalban X, Moraal B, Reich DS, Rovira A, Toosy AT, Traboulsee A, Weinshenker BG, Zeydan B, Banwell BL, Rocca MA. *JAMA Neurol.* 2020 Dec 14.
- 201.** Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS) Negri L, Minacapelli E, Bassi M, Cilia S, Falautano M, Grobberio M, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, **Gasparini C**, Patti F, Trojano M, Delle Fave A. *Neurol Sci.* 2020 Jul;41(7):1881-1889.
- 202.** Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression. Prosperini L, Haggiag S, Tortorella C, Galgani S, **Gasparini C**. *Mult Scler.* 2020
- 203.** Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study. Di Gregorio M, Torri Clerici VLA, Fenu G, Gaetani L, Gallo A, Cavalla P, Ragonese P, Annovazzi P, Gajofatto A, Prosperini L, Landi D, Nicoletti CG, Di Carmine C, Totaro R, Nociti V, De Fino C, Ferraro D, Tomassini V, Tortorella C, Righini I, Amato MP, Manni A, Paolicelli D, Iaffaldano P, Lanzillo R, Moccia M, Buttari F, Fantozzi R, Cerqua R, Zagaglia S, Farina D, De Luca G, Buscarinu MC, Pinardi F, Cocco E, **Gasparini C**, Solaro C, Di Filippo M. *Eur J Neurol.* 2020

- 204.** Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial Prosperini L, Castelli L, De Giglio L, Bonanno V, **Gasparini C**, Pozzilli C.. *Neurotherapeutics*. 2020
- 205.** Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. Prosperini L, Mancinelli CR, Solaro CM, Nociti V, Haggiag S, Cordioli C, De Giglio L, De Rossi N, Galgani S, Rasia S, Ruggieri S, Tortorella C, Capra R, Mirabella M, **Gasparini C**. *Neurotherapeutics*. 2020
- 206.** Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. Moccia M, Annovazzi P, Buscarinu MC, Calabrese M, Cavalla P, Cordioli C, Di Filippo M, Ferraro D, Gajofatto A, Gallo A, Lanzillo R, Laroni A, Loreface L, Mallucchi S, Nociti V, Paolicelli D, Pinardi F, Prosperini L, Radaelli M, Ragonese P, Tomassini V, Tortorella C, Cocco E, **Gasparini C**, Solaro C. *Mult Scler Relat Disord*. 2020
- 207.** Informing MS patients on treatment options: a consensus on the process of consent taking. Tortorella C, Solaro C, Annovazzi P, Boffa L, Buscarinu MC, Buttari F, Calabrese M, Cavalla P, Cocco E, Cordioli C, De Luca G, Di Filippo M, Fantozzi R, Ferraro D, Gajofatto A, Gallo A, Lanzillo R, Laroni A, Fermo SL, Malucchi S, Maniscalco GT, Moccia M, Nociti V, Paolicelli D, Pesci I, Prosperini L, Ragonese P, Tomassini V, Clerici VLAT, Rodegher M, Gherardi M, **Gasparini C**; RIReMS Group. *Neurol Sci*. 2020
- 208.** EBV- specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS Guerrera G, Ruggieri S, Picozza M, Piras E, Gargano F, Placido R, **Gasparini C**, Salvetti M, Buscarinu MC, Battistini L, Borsellino G, Angelini DF..*Neurol Neuroimmunol Neuroinflamm*. 2020
- 209.** Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study Chisari CG, Solaro C, Annunziata P, Bergamaschi R, Bianco A, Bonavita S, Brescia Morra V, Bruno Bossio R, Capello E, Castelli L, Cavalla P, Costantino G, Centonze D, Cottone S, Danni MC, Esposito F, Gajofatto A, **Gasparini C**, Guareschi A, Lanzillo R, Lus G, Maniscalco GT, Matta M, Paolicelli D, Petrucci L, Pontecorvo S, Righini I, Rovaris M, Sessa E, Spinicci G, Spitaleri D, Valentino P, Zaffaroni M, Zappia M, Patti F.. *J Neurol Neurosurg Psychiatry*. 2020
- 210.** The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease Gerald R, Juryńczyk M, Dos Passos GR, Pichler A, Chung K, Hagens M, Ruggieri S, Auger C, Sastre-Garriga J, Enzinger C, Chard D, Barkhof F, **Gasparini C**, Rovira A, DeLuca G, Palace J; MAGNIMS study group.. *Mult Scler*. 2020
- 211.** Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results. Capra R, Morra VB, Mirabella M, **Gasparini C**, Scandellari C, Totaro R, De Rossi N, Masera S, Zipoli V, Patti F; WANT Investigators. *Neurol Sci*. 2020
- 212.** Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. Patti F, Chisari CG, Solaro C, Benedetti MD, Berra E, Bianco A, Bruno Bossio R, Buttari F, Castelli L, Cavalla P, Cerqua R, Costantino G, **Gasparini C**, Guareschi A, Ippolito D, Lanzillo R, Maniscalco GT, Matta M, Paolicelli D, Petrucci L, Pontecorvo S, Righini I, Russo M, Saccà F, Salamone G, Signoriello E, Spinicci G, Spitaleri D, Tavazzi E, Trotta M, Zaffaroni M, Zappia M; SA.FE.group. *Neurol Sci*. 2020

213. Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double-blind, placebo-controlled, crossover study Solaro C, de Sire A, Messmer Uccelli M, Mueller M, Bergamaschi R, **Gasperini C**, Restivo DA, Stabile MR, Patti F.. Eur J Neurol. 2020

214. Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multicenter cohort de Sitter A, Verhoeven T, Burggraaff J, Liu Y, Simoes J, Ruggieri S, Palotai M, Brouwer I, Versteeg A, Wottschel V, Ropele S, Rocca MA, **Gasperini C**, Gallo A, Yiannakas MC, Rovira A, Enzinger C, Filippi M, De Stefano N, Kappos L, Frederiksen JL, Uitdehaag BMJ, Barkhof F, Guttman CRG, Vrenken H; MAGNIMS Study Group J Neurol. 2020

215. Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis Giorgio A, Battaglini M, Gentile G, Stromillo ML, **Gasperini C**, Visconti A, Paolillo A, De Stefano N. Front Neurol. 2020

216. Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support.

Bassi M, Cilia S, Falautano M, Grobberio M, Nicolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, **Gasperini C**, Minacapelli E, Patti F, Trojano M, Delle Fave A. Disabil Rehabil. 2020

217. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis.

Mantovani LG, Cozzolino P, Cortesi PA, Patti F; SA.FE. study group. Clin Drug Investig. 2020

2021

218. Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study.

Burggraaff J, Liu Y, Prieto JC, Simoes J, de Sitter A, Ruggieri S, Brouwer I, Lissenberg-Witte BI, Rocca MA, Valsasina P, Ropele S, **Gasperini C**, Gallo A, Pareto D, Sastre-Garriga J, Enzinger C, Filippi M, De Stefano N, Ciccarelli O, Hulst HE, Wattjes MP, Barkhof F, Uitdehaag BMJ, Vrenken H, Guttman CRG; MAGNIMS Study Group. Neuroimage Clin. 2021

219. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.

Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratini P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Musc-19 Study Group. Ann Neurol. 2021

220. Mind the gap: from neurons to networks to outcomes in multiple sclerosis.

Chard DT, Alahmadi AAS, Audoin B, Charalambous T, Enzinger C, Hulst HE, Rocca MA, Rovira A, Sastre-Garriga J, Schoonheim MM, Tijms B, Tur C, Gandini Wheeler-Kingshott CAM, Wink AM, Ciccarelli O, Barkhof F; MAGNIMS Study Group. Nat Rev Neurol. 2021

221. Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis.

Rocca MA, Valsasina P, Meani A, Gobbi C, Zecca C, Rovira A, Sastre-Garriga J, Kearney H, Ciccarelli O, Matthews L, Palace J, Gallo A, Bisecco A, Lukas C, Bellenberg B, Barkhof F, Vrenken H, Preziosa P, Filippi M; MAGNIMS Study Group. *Neurology*. 2021

222. Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study.

Burggraaff J, Liu Y, Prieto JC, Simoes J, de Sitter A, Ruggieri S, Brouwer I, Lissenberg-Witte BI, Rocca MA, Valsasina P, Ropele S, **Gasperini C**, Gallo A, Pareto D, Sastre-Garriga J, Enzinger C, Filippi M, De Stefano N, Ciccarelli O, Hulst HE, Wattjes MP, Barkhof F, Uitdehaag BMJ, Vrenken H, Guttman CRG; MAGNIMS Study Group. *Neuroimage Clin*. 2021

223. Tailored Vessel-Catheter Diameter Ratio in a Direct Aspiration First-Pass Technique: Is It a Matter of Caliber?

Pampuna E, Fabiano S, De Rubeis G, Bertaccini L, Stasolla A, Vallone A, Pingi A, Mangiardi M, Anticoli S, **Gasperini C**, Cotroneo E. *AJNR Am J Neuroradiol*. 2021

224. The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis.

Bassi M, Grobberio M, Negri L, Cilia S, Minacapelli E, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, Falautano M, **Gasperini C**, Patti F, Trojano M, Delle Fave A. *J Clin Psychol Med Settings*. 2021

225. Ozone-induced encephalopathy: A novel iatrogenic entity.

Haggiag S, Prosperini L, Stasolla A, Gerace C, Tortorella C, **Gasperini C**. *Eur J Neurol*. 2021

226. Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization.

De Stefano N, Giorgio A, Gentile G, Stromillo ML, Cortese R, **Gasperini C**, Visconti A, Sormani MP, Battaglini M. *Ann Clin Transl Neurol*. 2021

227. Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score.

Gasperini C, Prosperini L, Rovira A, Tintoré M, Sastre-Garriga J, Tortorella C, Haggiag S, Galgani S, Capra R, Pozzilli C, Montalban X, Río J. *Eur J Neurol*. 2021

228. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.

Lucchini M, Prosperini L, Buscarinu MC, Centonze D, Conte A, Cortese A, Elia G, Fantozzi R, Ferraro E, **Gasperini C**, Ianniello A, Landi D, Marfia GA, Nociti V, Pozzilli C, Salvetti M, Tortorella C, Mirabella M. *J Neurol*. 2021

229. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.

Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ; PREVENT Study Group. *Ann Neurol*. 2021 Feb 14. doi: 10.1002/ana.26049. Online ahead of print. PMID: 33586143

This analysis also demonstrated the sustained ability of long-term eculizumab treatment to reduce relapse risk in patients with AQP4-IgG+ NMOSD. *ANN NEUROL* **2021**....

230. Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references.

de Sitter A, Burggraaff J, Bartel F, Palotai M, Liu Y, Simoes J, Ruggieri S, Schregel K, Ropele S, Rocca MA, **Gasperini C**, Gallo A, Schoonheim MM, Amann M, Yiannakas M, Pareto D, Wattjes MP, Sastre-Garriga J, Kappos L, Filippi M, Enzinger C, Frederiksen J, Uitdehaag B, Guttman CRG, Barkhof F, Vrenken H. *Neuroimage Clin*. 2021

231. Switch Strategy from Direct Aspiration First Pass Technique to Solumbra Improves Technical Outcome in Endovascularly Treated Stroke.

Pampiana E, Fabiano S, De Rubeis G, Bertaccini L, Stasolla A, Pingi A, Cozzolino V, Mangiardi M, Anticoli S, **Gasperini C**, Cotroneo E. *Int J Environ Res Public Health*. 2021

232. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.

Bucello S, Annovazzi P, Ragonese P, Altieri M, Barcella V, Bergamaschi R, Bianchi A, Borriello G, Buscarinu MC, Callari G, Capobianco M, Capone F, Cavalla P, Cavarretta R, Cortese A, De Luca G, Di Filippo M, Dattola V, Fantozzi R, Ferraro E, Filippi MM, **Gasperini C**, Grimaldi LME, Landi D, Re ML, Mallucci G, Manganotti P, Marfia GA, Mirabella M, Perini P, Pisa M, Realmuto S, Russo M, Tomassini V, Torri-Clerici VLA, Zaffaroni M, Zuliani C, Zywicki S, Filippi M, Prosperini L. *J Neurol*. 2021

233. Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus.

Filippi M, Capra R, Centonze D, **Gasperini C**, Patti F, Perini P, Pozzilli C, Rocca MA, Uccelli A, Trojano M. *J Neurol*. 2021

234. A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia.

Ferraro D, Annovazzi P, Lanzillo R, Calabrese M, Fantozzi R, De Luca G, Cordioli C, Paolicelli D, Ragonese P, Gajofatto A, Lo Fermo S, Cavalla P, Tortorella C, Pesci I, Gallo A, Pinardi F, Di Filippo M, Maniscalco GT, Nociti V, Radaelli M, Tomassini V, Buscarinu MC, Moccia M, Camera V, Cocco E, **Gasperini C**, Solaro C. *J Neurol Sci*. 2021

235. Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.

Cortese R, Prosperini L, Stasolla A, Haggiag S, Villani V, Simone IL, **Gasperini C**, Tortorella C. *J Neurol*. 2021

236. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.

Centonze D, Rocca MA, **Gasperini C**, Kappos L, Hartung HP, Magyari M, Oreja-Guevara C, Trojano M, Wiendl H, Filippi M. *J Neurol*. 2021

237. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.

Baroncini D, Simone M, Iaffaldano P, Brescia Morra V, Lanzillo R, Filippi M, Romeo M, Patti F, Chisari CG, Cocco E, Fenu G, Salemi G, Ragonese P, Inglese M, Cellerino M, Margari L, Comi G, Zaffaroni M, Ghezzi A; Italian MS registry. *JAMA Neurol*. 2021

238. Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.

Granziera C, Wuerfel J, Barkhof F, Calabrese M, De Stefano N, Enzinger C, Evangelou N, Filippi M, Geurts JJG, Reich DS, Rocca MA, Ropele S, Rovira A, Sati P, Toosy AT, Vrenken H, Gandini Wheeler-Kingshott CAM, Kappos L; MAGNIMS Study Group. *Brain*. 2021 Jun 22;144(5):1296-1311.

- 239.** Natalizumab is associated with early improvement of working ability in relapsing remitting multiple sclerosis patients: WANT observational study results.
Capra R, Morra VB, Mirabella M, **Gasparini C**, Scandellari C, Totaro R, De Rossi N, Maserà S, Zipoli V, Patti F; WANT Investigators. *Neurol Sci*. 2021.
- 240.** Age-related adverse events of disease modifying treatments for multiple sclerosis: A meta-regression.
Prosperini L, Haggiag S, Tortorella C, Galgani S, **Gasparini C**. *Mult Scler*. 2021
- 241.** Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
Cortese R, Prosperini L, Stasolla A, Haggiag S, Villani V, Simone IL, **Gasparini C**, Tortorella C. *J Neurol*. 2021
- 242.** Real world experience with teriflunamide in multiple sclerosis : the TER-Italy study.
Bucello S, Annovazzi P, Ragonese P, Altieri M, Barcella V, Bergamaschi R, Bianchi A, Borriello G, Buscarinu MC, Callari G, Capobianco M, Capone F, Cavalla P, Cavarretta R, Cortese A, De Luca G, Di Filippo M, Dattola V, Fantozzi R, Ferraro E, Filippi MM, **Gasparini C**, Grimaldi LME, Landi D, Re ML, Mallucci G, Manganotti P, Marfia GA, Mirabella M, Perini P, Pisa M, Realmuto S, Russo M, Tomassini V, Torri-Clerici VLA, Zaffaroni M, Zuliani C, Zywicki S, Filippi M, Prosperini L. *J. Neurol* 2021
- 243.** Ozone-induced encephalopathy: A novel iatrogenic entity.
Haggiag S, Prosperini L, Stasolla A, Gerace C, Tortorella C, **Gasparini C**. *Eur J Neurol*. 2021
- 244.** Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score.
Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score.
Gasparini C, Prosperini L, Rovira À, Tintoré M, Sastre-Garriga J, Tortorella C, Haggiag S, Galgani S, Capra R, Pozzilli C, Montalban X, Río J. *Eur J Neurol*. 2021
- 245.** 2021 MAGNIMS – CMSC – NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, Fazekas F, Filippi M, Frederiksen J, **Gasparini C**, Hachimi Y, Kappos L, Li DK, Mankad K, Montalban X, Newsome SD, Oh J, Palace J, Rocca MA, Sastre-Garriga J, Tintoré M, Traboulsee A, Vrenken H, Yousry T, Barkhof F, Rovira À; Magnetic Resonance Imaging in Multiple Sclerosis study group; Consortium of Multiple Sclerosis Centres; North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. *Lancet Neurol*. 2021
- 246.** DMTs and Covid 19 severity in MS: a pooled analysis from Italy and France.
Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, Bensa C, De Rossi N, Pelletier J, Cordioli C, Vukusic S, Moiola L, Kerschen P, Radaelli M, Théaudin M, Immovilli P, Casez O, Capobianco M, Ciron J, Trojano M, Stankoff B, Créange A, Tedeschi G, Clavelou P, Comi G, Thouvenot E, Battaglia MA, Moreau T, Patti F, De Sèze J, Louapre C; Musc-19; Covisep study groups. *Ann Clin Transl Neurol*. 2021
- 247.** Stroke: Should we treat images or symptoms? A call for trial.
De Rubeis G, Pampana E, Fabiano S, Bertaccini L, Cotroneo E, **Gasparini C**. *Eur J Radiol*. 2021

248. Disease – modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.

Centonze D, Rocca MA, **Gasperini C**, Kappos L, Hartung HP, Magyari M, Oreja-Guevara C, Trojano M, Wiendl H, Filippi M. *J Neurol*. 2021

249. Prognostic Accuracy of NEDA – 3 in long-term Outcomes of Multiple Sclerosis

Prosperini L, Ruggieri S, Haggiag S, Tortorella C, Pozzilli C, **Gasperini C**.

Neurol Neuroimmunol Neuroinflamm. 2021

250. Opportunities of Understanding MS Mechanism and progression with MRI Using Large Scale Data Sharing and artificial Intelligence.

Vrenken H, Jenkinson M, Pham DL, Guttman CRG, Pareto D, Paardekooper M, de Sitter A, Rocca MA, Wottschel V, Cardoso MJ, Barkhof F; MAGNIMS Study Group.

Neurology. 2021

2022

251. Treatment response scoring systems to assess long term prognosis in self-injectable DMTs relapsing remitting multiple sclerosis patients.

Río J, Rovira À, **Gasperini C**, Tintoré M, Prosperini L, Otero-Romero S, Comabella M, Vidal-Jordana À, Galán I, Midaglia L, Rodriguez-Acevedo B, Zabalza A, Castelló J, Arrambide G, Nos C, Cobo Á, Tur C, Auger C, Sastre-Garriga J, Montalban X.

J Neurol. 2022

252. COVID – 19 severity in Multiple Sclerosis: Putting Data into Context.

Sormani MP, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, Immovilli P, Capobianco M, De Rossi N, Bricchetto G, Cocco E, Scandellari C, Cavalla P, Pesci I, Zito A, Confalonieri P, Marfia GA, Perini P, Inglese M, Trojano M, Brescia Morra V, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; MuSC-19 Study Group.

Neurol Neuroimmunol Neuroinflamm. 2021

253. Contribution of Rare and low frequency Variants to Multiple Sclerosis Susceptibility in the Italian Continental Population.

Clarelli F, Barizzone N, Mangano E, Zuccalà M, Basagni C, Anand S, Sorosina M, Mascia E, Santoro S; PROGEMUS; PROGRESSO, Guerini FR, Virgilio E, Gallo A, Pizzino A, Comi C, Martinelli V, Comi G, De Bellis G, Leone M, Filippi M, Esposito F, Bordoni R, Martinelli Boneschi F, D'Alfonso S.

Front Genet. 2022

254. Performance of the 2017 and 2010 Revised McDonald Criteria in predicting MS

Diagnosis after a Clinically Isolated Syndrome: A MAGNIMS study.

Filippi M, Preziosa P, Meani A, Dalla Costa G, Mesaros S, Drulovic J, Ivanovic J, Rovira A, Tintoré M, Montalban X, Ciccarelli O, Brownlee W, Miszkiel K, Enzinger C, Khalil M, Barkhof F, Strijbis EMM, Frederiksen JL, Cramer SP, Fainardi E, Amato MP, **Gasperini C**, Ruggieri S, Martinelli V, Comi G, Rocca MA; MAGNIMS Study Group.

Neurology. 2022

255. PML risk is the main factor driving the choice of discontinuing natalizumab in a large

multiple sclerosis population: result from an Italian multicenter retrospective study.
Chisari CG, Comi G, Filippi M, Paolicelli D, Iaffaldano P, Zaffaroni M, Brescia Morra V, Cocco E, Marfia GA, Grimaldi LM, Inglese M, Bonavita S, Lugaresi A, Salemi G, De Luca G, Cottone S, Conte A, Sola P, Aguglia U, Maniscalco GT, **Gasparini C**, Ferrò MT, Pesci I, Amato MP, Rovaris M, Solaro C, Lus G, Maimone D, Bergamaschi R, Granella F, Di Sapio A, Bertolotto A, Totaro R, Vianello M, Cavalla P, Bellantonio P, Lepore V, Patti F; Italian MS Register Study Group.
J Neurol. 2022

256. The effect of air pollution on COVID – 19 severity in a sample of patients with multiple sclerosis.

Bergamaschi R, Ponzano M, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, Immovilli P, Capobianco M, De Rossi N, Bricchetto G, Cocco E, Scandellari C, Cavalla P, Pesci I, Zito A, Confalonieri P, Marfia GA, Perini P, Inglese M, Trojano M, Brescia Morra V, Pisoni E, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M, Sormani MP; MuSC-19 study group.
Eur J Neurol. 2022

257. Humoral and T Cell Specific Immune Responses to SARS CoV 2 mRNA Vaccination in patients with MS using different disease modifying therapies

Tortorella C, Aiello A, **Gasparini C**, Agrati C, Castilletti C, Ruggieri S, Meschi S, Matusali G, Colavita F, Farroni C, Cuzzi G, Cimini E, Tartaglia E, Vanini V, Prosperini L, Haggiag S, Galgani S, Quartuccio ME, Salmi A, Repele F, Altera AMG, Cristofanelli F, D'Abramo A, Bevilacqua N, Corpolongo A, Puro V, Vaia F, Capobianchi MR, Ippolito G, Nicastrì E, Goletti D; INMI COVID-19 Vaccine Study Group.
Neurology 2022

258. Job satisfaction among physicians and nurses involved in the management of multiple sclerosis: the role of happiness and meaning at work.

Negri L, Cilia S, Falautano M, Grobberio M, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, **Gasparini C**, Minacapelli E, Patti F, Trojano M, Bassi M.
Neurol Sci. 2022

259. Increased risk of death from COVID 19 in multiple sclerosis: apooled analysis of observational studies.

Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, **Gasparini C**.
J Neurol. 2022

260. Cost effectiveness and budget impact analysis of Siponimod in the treatment of secondary progressive multiple sclerosis in Italy.

Cortesi PA, Antonazzo IC, **Gasparini C**, Nica M, Ritrovato D, Mantovani LG.
PLoS One. 2022

261. Natalizumab treatment and pregnancy in multiple sclerosis : A reappraisal of maternal and infant outcomes after 6 years.

Portaccio E, Pastò L, Razzolini L, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, **Gasparini C**, Paolicelli D, Simone M, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Comi G, Filippi M, Trojano M, Amato MP.
Mult Scler. 2022

262. mRNA COVID 19 vaccines do not increase the short term risk of clinical relapses in multiple sclerosis.

Di Filippo M, Cordioli C, Malucchi S, Annovazzi P, Cavalla P, Torri Clerici V, Ragonese P, Nociti V, Radaelli M, Laroni A, Buttari F, Loreface L, Ferraro D, Gajofatto A, Prosperini L, Fantozzi R, Boffa L, Lanzillo R, Moccia M, Clerico M, De Luca G, Tomassini V, Calabrese M, Borrelli A, Paolicelli D, Maniscalco GT, Gazzola P, Gallo A, Solaro C, Cocco E, **Gasparini C**, Tortorella C; RIREMS (Rising Researchers in MS) group. *J Neurol Neurosurg Psychiatry*. 2022

263. Shift of multiple sclerosis onset towards older age.

Prosperini L, Lucchini M, Ruggieri S, Tortorella C, Haggiag S, Mirabella M, Pozzilli C, **Gasparini C**.
J Neurol Neurosurg Psychiatry. 2022

264. Characterizing 1 year development of cervical cord atrophy across different MS phenotypes: a voxels wise multicentre analysis

Valsasina P, Gobbi C, Zecca C, Rovira A, Sastre-Garriga J, Kearney H, Yiannakas M, Matthews L, Palace J, Gallo A, Bisecco A, Gass A, Eisele P, Filippi M, Rocca MA; MAGNIMS Study Group;. *Mult Scler*. 2022

265. Determinants of COVID 19 related lethality in multiple sclerosis: a meta regression of observational studies.

Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, **Gasparini C**.
J Neurol. 2022

266. Non traumatic acute myelopathies: clinical and imaging features in a real world emergency setting.

Stasolla A, Prosperini L, Haggiag S, Pezzella FR, Pingi A, Cozzolino V, Pampana E, Cotroneo E, Tortorella C, Menniti A, **Gasparini C**.
Neuroradiol J. 2022

267. Efficacy of prolonged release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE.

Hupperts R, **Gasparini C**, Lycke J, Ziemssen T, Feys P, Xiao S, Acosta C, Koster T, Hobart J. *Ther Adv Neurol Disord*. 2022

268. [Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.](#)

Early use of high-efficacy disease modifying therapies makes difference in people with multiple sclerosis: an expert opinion.

Filippi M, Amato MP, Centonze D, Gallo P, **Gasparini C**, Inglese M, Patti F, Pozzilli C, Preziosa P, Trojano M.
J Neurol. 2022

269. Humoral and cellular response to spike of delta SARS CoV 2 Variant in Vaccinated patients with multiple sclerosis.

Petrone L, Tortorella C, Aiello A, Farroni C, Ruggieri S, Castilletti C, Meschi S, Cuzzi G,

Vanini V, Palmieri F, Prosperini L, Haggiag S, Galgani S, Grifoni A, Sette A, **Gasparini C**, Nicastrì E, Goletti D.
Front Neurol. 2022

270. SARS CoV 2 serology after COVID 19 in multiple sclerosis: an international cohort study.

Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Brescia Morra V, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Furlan R, Salvetti M; MuSC-19 Study Group.

Mult Scler. 2022

271. Management of hepatitis B virus prophylaxis in patients treated with disease modifying therapies for multiple sclerosis : amulticentric Italian retrospective study.

Buonomo AR, Viceconte G, Calabrese M, De Luca G, Tomassini V, Cavalla P, Maniscalco GT, Ferraro D, Nociti V, Radaelli M, Buscarinu MC, Paolicelli D, Gajofatto A, Annovazzi P, Pinardi F, Di Filippo M, Cordioli C, Zappulo E, Scotto R, Gentile I, Spiezia AL, Petruzzio M, De Angelis M, Brescia Morra V, Solaro C, **Gasparini C**, Cocco E, Moccia M, Lanzillo R; Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group.

J Neurol. 2022

272. Correction to: management of hepatitis B virus prophylaxis in patients treated with disease modifying therapies for multiple sclerosis : amulticentric Italian retrospective study.

Buonomo AR, Viceconte G, Calabrese M, De Luca G, Tomassini V, Cavalla P, Maniscalco GT, Ferraro D, Nociti V, Radaelli M, Buscarinu MC, Paolicelli D, Gajofatto A, Annovazzi P, Pinardi F, Di Filippo M, Cordioli C, Zappulo E, Scotto R, Gentile I, Spiezia AL, Petruzzio M, De Angelis M, Morra VB, Solaro C, **Gasparini C**, Cocco E, Moccia M, Lanzillo R; Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group.

J Neurol. 2022

273. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis

Carod-Artal FJ, Adjamian P, Vila Silván C, Bagul M, **Gasparini C**.

Expert Rev Neurother. 2022

274. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.

Bergamaschi R, Beghi E, Bosetti C, Ponzio M, Santucci C, Lepore V, Mosconi P; Italian Multiple Sclerosis and Related Disorders Register Centers Group and the Scientific Committee of Italian SM and Related Disorders Register, Aguglia U, Amato MP, Ancona AL, Ardito B, Avolio C, Balgera R, Banfi P, Barcella V, Barone P, Bellantonio P, Berardinelli A, Bergamaschi R, Bertora P, Bianchi M, Bramanti P, Morra VB, Bricchetto G, Brioschi AM, Buccafusca M, Bucello S, Busillo V, Calchetti B, Cantello R, Capobianco M, Capone F, Capone L, Cargnelutti D, Carrozzi M, Cartechini E, Cavaletti G, Cavalla P, Celani MG, Clerici R, Clerico M, Cocco E, Confalonieri P, Coniglio MG, Conte A, Corea F, Cottone S, Crociani P, D'Andrea F, Danni MC, De Luca G, de Pascalis D, De Riz M, De Robertis F, De Rosa G, De Stefano N, Corte MD, Di Sapio A, Docimo R, Falcini M, Falcone N, Fermi S, Ferraro E, Ferrò MT, Fortunato M, Foschi M, Gajofatto A, Gallo A, Gallo P, Gatto M, Gazzola P, Giordano A, Granella F, Grasso MF, Grasso MG, Grimaldi LME, Iaffaldano P, Imperiale D, Inglese M, Iodice R, Leva S, Luezzi V, Lugaresi A, Lus G, Maimone D, Mancinelli L, Maniscalco GT, Marfia GA, Marini B, Marson A, Mascoli N, Massacesi L, Melani F, Merello M, Meucci G, Mirabella M, Montepietra S, Nasuelli D,

Nicolao P, Passantino F, Patti F, Peresson M, Pesci I, Piantadosi C, Piras ML, Pizzorno M, Plewnia K, Pozzilli C, Protti A, Quatrate R, Realmuto S, Ribizzi G, Rinalduzzi S, Rini A, Romano S, Romeo M, Ronzoni M, Rossi P, Rovaris M, Salemi G, Santangelo G, Santangelo M, Santuccio G, Sarchielli P, Sinisi L, Sola P, Solaro C, Spitaleri D, Strumia S, Tassinari T, Tonietti S, Tortorella C, Totaro R, Tozzo A, Trivelli G, Ulivelli M, Valentino P, Venturi S, Vianello M, Zaffaroni M, Zarbo R, Trojano M, Battaglia MA, Capobianco M, Pugliatti M, Ulivelli M, Mosconi P, **Gasparini C**, Patti F, Amato MP, Bergamaschi R, Comi G.
Neurol Sci. 2022

275. Dural arteriovenous fistula as a reversible cause of progressive parkinsonism and dementia: a case report.
Prosperini L, Gentile M, Ricci M, Gerace C, Fabiano S, Stasolla A, **Gasparini C**, Cotroneo E.
Neurohospitalist. 2022

276. Long term follow up (up to 11 years) of an italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.
Baroncini D, Ghezzi A, Guaschino C, Moiola L, Filippi M, Ianniello A, Pozzilli C, Lanzillo R, Brescia-Morra V, Margoni M, Gallo P, Callari G, Grimaldi L, Lus G, Calabrese M, Simone M, Marfia GA, Rasia S, Cargnelutti D, Comi G, Zaffaroni M; MS Study Group of the Italian Neurological Society.
Neurol Sci. 2022

277. Accuracy of QuantiFERON SARS CoV 2 RUO assay and characterization of the CD4+ and CD8+ T cell SARS CoV 2 response: comparison with a home made IFN gamma release assay.
Aiello A, Coppola A, Vanini V, Petrone L, Cuzzi G, Salmi A, Altera AMG, Tortorella C, Gualano G, **Gasparini C**, Scolieri P, Beccacece A, Vita S, Bruzzese V, Lorenzetti R, Palmieri F, Nicastrì E, Goletti D.
Int J Infect Dis. 2022

278. A multi step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
Sorosina M, Barizzone N, Clarelli F, Anand S, Lupoli S, Salvi E, Mangano E, Bordoni R, Roostaei T, Mascia E, Zuccalà M, Vecchio D, Cavalla P, Santoro S, Ferrè L, Zollo A; PROGEMUS, Barlassina C, Cusi D, Martinelli V, Comi G, Leone M, Filippi M, Patsopoulos NA, De Jager PL, De Bellis G, Esposito F, D'Alfonso S, Martinelli Boneschi F
J Neurol. 2022

279. Correction to: A multi step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility Sorosina M, Barizzone N, Clarelli F, Anand S, Lupoli S, Salvi E, Mangano E, Bordoni R, Roostaei T, Mascia E, Zuccalà M, Vecchio D, Cavalla P, Santoro S, Ferrè L, Zollo A; PROGEMUS, Barlassina C, Cusi D, Martinelli V, Comi G, Leone M, Filippi M, Patsopoulos NA, De Jager PL, De Bellis G, Esposito F, D'Alfonso S, Martinelli Boneschi F.
J Neurol. 2022

10 aprile 2022.

Claudio Gasparini

Programma Dott. Claudio Gasperini per candidatura a segretario del Gruppo di Studio SIN "Sclerosi Multipla"

La presentazione di questa candidatura nasce dalla costante partecipazione al lavoro svolto dal GdS da diversi anni e dal desiderio di darne continuità.

Obiettivo primario sarà quello di coordinare le attività del Gruppo di Studio sia in ambito scientifico che clinico assistenziale

In ambito scientifico, di concerto con la SIN saranno obiettivi primari:

1. Favorire studi collaborativi, incentivando le collaborazioni tra i centri italiani e con società scientifiche nazionali ed internazionali
2. Potenziare la collaborazione con il registro Italiano SM
3. Dare continuità al ruolo educativo del GdS favorendo convegni, seminari e congressi, e stimolando la partecipazione di ogni operatore sanitario, dei giovani in particolare, che possa essere coinvolto a qualsiasi titolo nella gestione del paziente con Sclerosi multipla

In ambito assistenziale, di concerto con la SIN saranno obiettivi primari:

1. Avere ruolo di advisor per le Regioni ed eventualmente per il Ministero ed AIFA in ordine alle scelte su innovazioni tecnologiche (accesso a servizi, farmaci, presidi della riabilitazione)
2. Stimolare ed ampliare il dibattito clinico-assistenziale, sviluppando la produzione di percorsi volti a migliorare l'interazione ospedale-territorio.
3. Avere ruolo di advisor per AISM e FISM, tenendo sempre l'autonomia di appartenenza.
4. Potenziare l'interazione tra i centri distribuiti sul territorio nazionale favorendo la centralità del paziente.

Roma 10 aprile 2023

